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There is an urgent need for new tools for the rapid diagnosis of tuberculosis (TB) disease and 




To investigate the usefulness of host markers detected in plasma and saliva, as well as 
antibodies against M. tuberculosis (M.tb) antigens, as biomarkers for the diagnosis of TB 
disease and monitoring of the response to treatment. To investigate the usefulness of a 
diagnostic approach involving the combination of antibodies and cytokines as a tool for 
diagnosing TB disease. 
METHODS:  
 
We prospectively collected plasma and saliva samples from individuals that presented with 
symptoms requiring investigation for TB disease at a health centre in Cape Town, South Africa, 
prior to the establishment of a clinical diagnosis. Patients were later classified as having TB 
disease or other respiratory diseases (ORD), using a combination of clinical, radiological and 
laboratory findings. The concentrations of host inflammatory biomarkers were investigated 
in plasma and saliva samples from all study participants using a multiplex platform, whereas 
antibody responses against seven M.tb antigens, were investigated by ELISA. The diagnostic 
accuracies of individual biomarkers were assessed by receiver operator characteristics (ROC) 
curve analysis, whereas the accuracies of combinations between different biomarkers were 




Of the 74 host markers evaluated in plasma, 18 showed diagnostic potential as determined 
by area under the ROC  curve (AUC), with the most promising being NCAM, CRP, SAP, IP-10, 
ferritin, TPA, I-309, and MIG, which diagnosed TB disease individually with AUC  ≥0.80. A six-
marker plasma protein biosignature comprising of NCAM, SAP, IL-1β, sCD40L, IL-13 and Apo 
A-1 diagnosed TB disease with a sensitivity of 100% (95% CI, 86.3-100%) and specificity of 
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89.3% (95% CI, 67.6-97.3%), irrespective of HIV status, whereas six-marker plasma protein 
biosignatures diagnosed TB disease with 100% accuracy in the absence of HIV. Of the 69 host 
markers that were investigated in saliva, only two (IL-16 and IL-23) showed diagnostic 
potential with AUC ≥0.70. A five-marker salivary biosignature comprising of IL-1β, IL-23, ECM-
1, HCC1 and fibrinogen diagnosed TB disease with a sensitivity of 88.9% (95% CI,76.7-99.9%) 
and specificity of 89.7% (95% CI, 60.4-96.6%), regardless of HIV infection status, whereas 
eight-marker salivary biosignatures performed with a sensitivity of 100% (95% CI, 83.2-100%) 
and specificity of 95% (95% CI, 68.1-99.9%) in the absence of HIV infection. IgA responses 
against four M.tb antigens (NarL, Rv3019c, “Kit1” and “Kit2”) were significantly different 
between TB patients and individuals with ORD, with combinations between different 
antibodies diagnosing TB disease with an AUC of 0.80. The diagnostic accuracy of the 
antibodies increased when used in combination with patient’s symptoms or cytokines. Finally, 
the concentrations of biomarkers detected in plasma and saliva changed during TB treatment, 




We have identified novel plasma and salivary biosignatures which may be useful in the 
diagnosis of TB disease and monitoring of the response to TB treatment. Our findings require 











Daar is 'n dringende behoefte aan nuwe toestelle vir die vinnige diagnose van tuberkulose ( 
TB ) en monitering van die reaksie op behandeling. 
 
DOELWITTE 
Om die nut van gasheer merkers in plasma en speeksel waar te neem , sowel as 
teenliggaampies teen M. tuberculosis ( M.tb ) antigene , as biomerkers vir die diagnose van 
TB en monitering van die reaksie op behandeling te ondersoek . Om die nut van 'n 
diagnostiese benadering met betrekking tot die kombinasie van teenliggaampies en sitokiene 
as 'n toestel vir die diagnose van TB te ondersoek. 
 
METODES 
Ons het plasma en speeksel monsters van individue met simptome wat tot die ondersoek van  
TB dui vooruitwerkend ingesamel by 'n gesondheidsentrum in Kaapstad , Suid-Afrika , voor 
die vestiging van 'n kliniese diagnose. Pasiënte was later geklassifiseer as TB of ander 
respiratoriese siektes (ARD) pasiënte, met behulp van 'n kombinasie van kliniese , radiologiese 
en laboratorium bevindings. Die konsentrasies van die gasheer inflammatoriese biomerkers 
in al die studie deelnemers in plasma en speeksel monsters was ondersoek met behulp van 'n 
multiplex platform , terwyl teenliggaam response teen sewe M.tb antigene , ondersoek was 
met ELISA . Die diagnostiese akkuraatheid van individuele biomerkers is beoordeel deur 
ontvanger operateur eienskappe (OOC) kurwe analise ,terwyl die akkuraatheid van 
kombinasies tussen verskillende biomerkers beoordeel was deur Algemene Diskriminant 
Analise ( GDA ) . 
 
RESULTATE 
Van die 74 gasheer merkers wat geëvalueer was in plasma het 18 diagnostiese potensiaal 
gehad soos bepaal deur area onder die OOC kurwe (AOC), met NCAM, CRP, SAP, IP-10, 
Ferritin, TPA, I-309, en MIG as die mees belowende merkers wat TB  individueel diagnoseer  
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met AOC ≥0.80. 'n Ses-merker plasmaproteïen biosignature bestaande uit NCAM, SAP, IL-1β, 
sCD40L, IL-13 en Apo A-1 het TB gediagnoseer met 'n sensitiwiteit van 100% (95% CI, 86,3-
100%) en spesifisiteit van 89,3 % (95% CI, 67,6-97,3%), ongeag MIV-status, terwyl ‘n ses-
merker plasmaproteïen biosignatures TB gediagnoseer het met 100% akkuraatheid in die 
afwesigheid van MIV. Van die 69 gasheer merkers wat ondersoek was in speeksel het slegs 
twee (IL-16 en IL-23) diagnostiese potensiaal getoon met AOC ≥0.70. 'n Vyf-merker speeksel 
biosignature bestaande uit IL-1β, IL-23, ECM-1, HCC1 en fibrinogeen het TB gediagnoseer met 
'n sensitiwiteit van 88,9% (95% CI, 76,7-99,9%) en spesifisiteit van 89,7% (95% GI, 60,4-96,6%), 
ongeag van MIV-infeksie status, terwyl agt-merker speeksel biosignatures gegenereer was 
met 'n sensitiwiteit van 100% (95% CI, 83,2-100%) en spesifisiteit van 95% (95% CI, 68,1-99,9 
%) in die afwesigheid van MIV-infeksie. IgA reaksies teen vier M.tb antigene (NarL, Rv3019c, 
"Kit1" en "Kit2") het aansienlik verskil tussen TB-pasiënte en individue met ARD, met 
kombinasies tussen verskillende teenliggaampies wat TB diagnoseer  met 'n AOC van 0.80. 
Die diagnostiese akkuraatheid van die teenliggaampies verhoog wanneer dit gebruik word in 
kombinasie met pasiënt simptome of sitokiene. Ten slotte, die konsentrasies van biomerkers 
wat in plasma en speeksel ondersoek was verander tydens TB behandeling, en dui sodoende 
aan dat hulle nuttig kan wees in die monitering van die reaksie op TB behandeling. 
 
GEVOLGTREKKING 
Ons het nuwe plasma en speeksel biosignatures geïdentifiseer wat nuttig kan wees in die 
diagnose van TB en monitering van die reaksie op TB behandeling. Ons bevindinge vereis 
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Tuberculosis (TB) is a leading death causing infectious disease, primarily infecting mammalian 
airways. TB is known to be caused by the Mycobacterium tuberculosis (M.tb) complex 
comprising of M. tuberculosis, M. bovis, M. africanum, M. microtti and M. canetti, with M. 
tuberculosis being the most prevalent in humans [1]. M.tb is an obligated aerobic bacillus, 
with a robust cell wall, with long- chain fatty acids and glycolipids [2]. It is categorised as a 
slow growing organism with a generation time of 18-48 hours, consequently causing TB 
disease progression to be reasonably slower compared to other infectious diseases [3]. The 
lungs are the most important site for the bacterium to manifest itself as the disease is 
transmitted almost exclusively by cough droplets from individuals with active pulmonary 
disease [4, 5]. These droplets (containing the bacilli) are subsequently inhaled into the 
respiratory tract where it infects the lungs that are highly aerobic and contains large measures 
of oxygen [6]. Though pulmonary TB occurs more frequently, extrapulmonary TB is also 
problematic as the bacilli can spread from the lungs to other parts of the body, through the 
lymphatic or blood circulating system, consequently causing extrapulmonary TB of the 
lymphatics, genitourinary system and meninges amongst others [7]. The global TB epidemic 
is also driven to a large extent by the human immunodeficiency virus (HIV) co-epidemic [8]. It 
is known that a higher risk of TB exists among HIV infected individuals [9]. Disseminated TB 
refers to two or more organs being infected simultaneously and it has been shown that HIV 
co-infection has further extended the possibility of mycobacterial dissemination due to 
immune deficiency, resulting in poor cell mediated immunity [10].  
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1.2 TB Epidemiology 
 
Since the World Health Organisation (WHO) declared tuberculosis as a global emergency, TB 
mortality has fallen by 47% [9]. Despite the decline in the mortality percentage due to 
effective diagnosis and treatment of TB, disease burden remains remarkably significant. In 
2014, six million new active tuberculosis cases and 1.5 million deaths (including 390,000 
deaths among HIV-infected individuals) were reported worldwide [9]. The TB epidemic seems 
to be of even greater concern with the occurrence of multi-drug resistant strains of M.tb. It 
has been estimated that 3.3% of new TB cases and 20% of previous cases have multidrug-
resistant tuberculosis (MDR-TB).It has been recognised that regions in Africa had the highest 
rates of TB per capita (281 cases per 100 000 people) [9].  
 
 
Figure 1.1: World map indicating the estimated TB incidence rate in 2014. Source: WHO TB 
report 2015 [9]. 
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1.3 General Immunology 
 
The human body is exposed to various microbial organisms on a daily basis. Fortunately, the 
body’s immune system is distinctively developed to prevent infections and to eradicate 
established infections. This system of defence is mediated by a collection of immune cells and 
several other molecules. Immune cells are primarily known to develop in the bone marrow. 
However, the maturation and activation of these cells generally occurs in the secondary 
lymphoid organs involving the thymus, spleen and lymph nodes [11, 12]. These cells are able 
to migrate between tissues and interact with one another ultimately leading to a specific 
immune response. The human immune system has been divided into two categories; innate 
and adaptive immunity [13]. 
  
Innate immunity can be seen as the body’s first line of defence that aids in protecting against 
common pathogens by means of a rapid and non-specific response. In contrast, adaptive 
immunity is more specific and therefore enables a more effective response [13]. These two 
types of immune responses respectively have their own specific cells that are responsible for 
their protective functions. Innate immunity consists of mast cells, basophils, eosinophils and 
phagocytes that are responsible for ingesting material that the body perceives as foreign [13]. 
Circulating phagocytes include neutrophils which are mostly found in areas of inflammation, 
monocytes, which differentiate into macrophages and dendritic cells that have essential 
antigen presentation functions [14–16]. Furthermore the innate immune system ,in part, 
initiates and activates the adaptive immune system [17]. B, as well as T-cells are key mediators 
of the adaptive immune system[13]. B-cells are known to produce antibodies that are 
responsible for eliminating extracellular microbial antigens. These antibodies also have the 
ability to mediate responses within the innate immune system by amplifying the ingestion of 
phagocytes [18, 19]. The two main T-cells are the cluster of differentiation (CD)4+ cells, that 
aid in the production of antibodies and assist in phagocyte activation, and CD8+ T-cells which 
are responsible for destroying virally infected cells [20, 21]. According to the cytokine 
secretion profiles, CD4 T cells can be classified as T helper 1 (Th1), Th2 or regulatory T-cells 
(Tregs) [20]. In addition unconventional T-cells such as gamma/delta T-cells also exist and are 
known to have distinctive T-cell receptors on their surface [13]. Gamma/delta T-cells are 
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functionally known to exert cytotoxic activity. Studies have also shown that these T-cells can 
serve as a bridge between innate and adaptive immune responses [22].Additionally, innate 
and adaptive immune cells are able to produce molecules, called cytokines and chemokines, 
which are of particular importance during the development of the immune response by 
mediating division and differentiation of stem cells and activating lymphocytes (T-cells) and 
phagocytes [23–26]. 
 
1.4 Immune Responses to M.tb Infection 
 
After exposure to M.tb, it is infrequent that the individual would go on to develop 
symptomatic disease. Therefore, although a third of the world’s population is infected with 
M.tb, only about 5-10% actually develop active disease as others would be known as being 
latently infected (asymptomatic disease). This differential outcome of infection was 
demonstrated in 1926 in Lubeck, Germany, when infants were unintentionally vaccinated 
with a live M.tb strain instead of the M. bovis Bacillus Calmette -Guerin (BCG) vaccine strain 
[27].  Some of the infants went on to develop active TB disease, while others remained 
unaffected. This unfortunate event therefore demonstrated that some individuals have a 
natural immunity to M.tb, thereby revealing that the host immune response in certain 
individuals is adequate to protect against M.tb. Still an incomplete understanding remains as 
to why some individuals are protected against M.tb while others go on to develop disease. 
Although the protective mechanisms against M.tb are not fully understood, it is known that 
it involves an extensive range of both innate and adaptive immune responses [28, 29]. Earlier 
studies showed that the initial host response against M.tb involves the influx of phagocytes 
primarily including alveolar macrophages, neutrophils and dendritic cells [30]. Once the 
bacterium has been inhaled into the airways, it is taken up by alveolar macrophages and 
neutrophils [30]. Activated macrophages further initiate an immune response by inducing 
inflammatory responses via the production of various pro-inflammatory cytokines including 
tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, IL-12 and IL-18 as well as anti-
inflammatory IL-10 [31–34]. In addition, chemokines including CCL2, CXCL10 are also 
produced to facilitate the recruitment and migration of additional macrophages and dendritic 
cells to the site of infection [33, 34]. Upon recognition of the invading bacteria, these dendritic 
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cells are also responsible for internalizing M.tb as well as upregulating the expression of 
various cytokines before migrating and maturing in draining lymph nodes, under the influence 
of IL-12, where they are responsible to prime naïve T-cells via antigen presentation towards 
a Th1 phenotype [35, 36]. Inflammation in the lungs causes effector CD4+ Th1 cells to migrate 
back to the site of infection (lungs) in a chemokine dependent manner where these cells 
produce TNF-α and Interferon-gamma (IFN-γ), which is needed for macrophage activation and 
the control of TB disease [37–39]. Flynn et al. demonstrated the importance of IFN-γ in the 
control of TB disease, and showed that IFN-γ gene depleted mice are highly susceptible to 
M.tb, with defects in the activation of macrophages and unrestrained bacilli growth [40]. IFN-
γ is therefore important in determining susceptibility to TB disease as well as in determining 
disease severity and treatment outcome [41, 42]. 
 
Once the Th1 cells migrate to the lungs (during pulmonary TB) , granulomas are formed which 
are seen as the hallmark of M.tb infection [43]. TNF-α, produced by macrophages and CD4+ 
T-cells, plays an important role in granuloma formation [44].  Granulomas are normally 
associated with highly activated immune responses and comprise of a collection of immune 
cells including macrophages, CD4+-, and CD8+- T cells, as well as B-cells [45]. These immune 
cells controls the infection by interacting with each other, subsequently resulting in an 
effective immune response, through the production of cytokines, activation of macrophages 
and T-cell responses that ultimately leads to killing M.tb [46–48]. Granulomas also contains 
the bacilli and thus prevents the spread of infection [49]. Consequently the resulting 
pathology can also create additional problems for the human host. Granulomas are also able 
to form an area of necrosis when excessive inflammation occurs, which would liquefy 
therefore providing infectious bacilli for further transmission [50, 51]. Studies also report that 
M.tb is able to induce apoptosis of macrophages that are located within the granuloma [52]. 
In addition to the importance of cell-mediated immunity in TB, humoral immunity is also 
significant in the fight against M.tb. Although M.tb is an intracellular pathogen, it is known 
that it also has an extracellular phase where it can be found in the upper respiratory tract 
during early infection also during more progressive phases after granulomas are ruptured 
[53].Therefore apart from their role in the granuloma, B-cells also produce antibodies that aid 
in the regulation of the induction of T-cell immunity against intracellular pathogens. 
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Moreover Rodriguez et al. demonstrated that after  immunization, IgA deficient mice were 
found to be more susceptible to BCG infection in comparison to wild type mice [54]. 
Furthermore the analysis of cytokine responses demonstrated that IFN-γ and TNF-α 
production is reduced, thereby suggesting the importance of IgA in protecting against 
mycobacterial infections [54]. 
 
1.5 Diagnosis of TB Disease 
 
An important aspect in the global control of TB disease includes the improvement of case 
finding, since several TB cases (about 3 million) are undiagnosed [55]. Additionally, this would 
result in a reduction in transmission of M.tb [55]. The clinical symptoms of pulmonary TB is a 
reflection of the host response to the bacterium. These symptoms include chronic cough, 
fever, weight loss, night sweats and hemoptysis [56]. Further examination findings would 
include radiological abnormalities such as lung cavities or densities [55]. However confirming 
the diagnosis of TB disease remains difficult as these clinical features are not specific to TB 
and overlap with other diseases such as lung cancer and pneumonia, resulting in delays before 
a practitioner would consider diagnosing a patient with active TB. Therefore in addition to 
clinical suspicion, employment of other methods are essential in order to confirm active TB 
disease.  
  
1.5.1 Current Diagnostic Methods 
 
Sputum smear microscopy is still the most frequently used method to determine the presence 
of mycobacteria, and is recommend by WHO and International Union Against Tuberculosis 
and Lung Disease (IUATLD) as the most appropriate method in TB endemic countries [57]. This 
method is relatively easy and cost effective, making it suitable for use in low-income 
countries. A more rapid form of this method exists, with the use of fluorescent staining and 
computer automated microscope reading, which would limit human errors especially false 
negative results [58]. However the use of this modified version would not be suitable in 
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resource-poor settings, due to high costs. Although sputum microscopy is highly specific, it 
has a variable sensitivity (32-97%) as the detection limit of microscopy is 104 bacteria/ml [59]. 
Studies have also shown that this method is less sensitive in individuals who are co-infected 
with HIV, and are more likely to result in having a negative sputum smear [60]. Furthermore, 
smear microscopy is unable to differentiate between M.tb and other nontuberculous 
mycobacteria and therefore requires further isolation and confirmation of M.tb [59]. One way 
of achieving this is through mycobacterial culture. Culture is regarded as the ‘gold standard’ 
for the diagnosis of TB disease. It is highly specific and more sensitive than microscopy, as 
only 10 bacteria/ml is needed for the detection of M.tb [61]. However since M.tb is a slow 
growing organism, it can take up to 6-8 weeks to confirm diagnosis. A recent advance in the 
TB diagnostic field was the automated Nucleic acid amplification technique, GeneXpert 
(Cepheid Inc., Sunnyvale, USA). This technique is able to deliver results within 2 hours, and is 
also able to detect resistance to rifampicin, as a proxy for MDR-TB [62]. It is highly sensitive 
and specific, compared to culture, with its sensitivity varying from 74-100% and specificity 
from 95-100% [63]. The use of GeneXpert is expensive and has high infrastructural needs that 
is not always obtainable in resource-poor settings, consequently creating a major obstacle for 
its use in these settings. If obtainable, in South Africa for example, the GeneXpert test is 
mostly available in centralized facilities, meaning that specimens collected at the peripheral 
level health care centres still have to be shipped to these central laboratories for testing. The 
usefulness of these sputum based tests is also limited in the difficult-to-diagnose patient 
groups, such as those with paediatric and extrapulmonary TB. A urine lipoarabinomannan 
(LAM) point-of-care lateral flow assay (Alere DetermineTM TB LAM Ag, Alere Inc, Waltham, 
MA, USA) has recently been developed and has been proven to be accurate for use as a rapid 
rule-in test for TB in hospitalised individuals with advanced immunosuppression due to HIV 
infection [64]. 
1.5.2 Immunological Diagnosis of TB Disease 
 
M.tb infection (latent infection) is typically demonstrated by the host’s reactivity to M.tb 
antigens. The tuberculin skin test (TST), a test which involves the administration of purified 
protein derivative (PPD) via intradermal injection, is the oldest M.tb infection diagnostic test, 
and has been in use for more than a century [65]. After administration of PPD, the ensuing 
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delayed type hypersensitivity immune response results in a visible induration that is 
measured 48-72 hours after injection [66]. The induration is measured in millimetres 
(mm)[66]. Although the TST is the cheapest and most widely available test for diagnosing M.tb 
infection, the test has several limitations as several factors are known to bring about false 
negative results including age, nutrition or immunosuppression [67]. Additionally, false 
positive results are a concern as PPD contains over 200 antigens that are also found in 
nontuberculous mycobacteria (NTM) and in the M. bovis BCG vaccine. It is therefore not 
highly specific [68].  
 
Advances in genomic research led to the discovery of the early secretory antigenic target-6 
(ESAT-6) and culture filtrate protein-10 (CFP-10), which are contained within the region of 
difference. As this region is present in pathogenic M.tb but absent in the BCG vaccine strains 
and most NTM, the discovery of ESAT-6 and CFP-10 led to the development of the so called 
Interferon Gamma Release Assay (IGRAs), which are now regarded as the gold standard tests 
for M.tb infection in some settings [69]. These assays are based on the principle that 
individuals who have been exposed to M.tb harbour pre-activated T cells, which respond 
rapidly, with the production of cytokines after re-challenge with M.tb specific antigens. 
Reactivity to these antigens in IGRAs is assessed through the measurement of IFN-γ produced 
after overnight culture in an enzyme-linked immunosorbent assay (Quantiferon TB Gold 
assays) or by the enzyme-linked immunosorbent technique in the case of the T.SPOT test 
[69][65]. Although IGRAs have been shown to be very useful in diagnosing M.tb infection, 
particularly compared to the TST, the use of these tests are restricted in high TB endemic 
areas, as these tests do not differentiate between latent M.tb infection and active TB disease. 
This is therefore one of the main setbacks in these settings because of the high prevalence of 
latent infection. Currently, there are no commercially available tests that are able to 
differentiate between latent and active TB disease. Serological diagnosis of TB disease is 
another immunological approach. However, the WHO banned the use of all commercially 
available serological diagnostic tests in 2011 [70]. 
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1.5.3 New Approaches towards the Immunological Diagnosis of TB Disease 
 
In order to improve the current situation where TB case detection and diagnostic capacity is 
suboptimum [9], it is important that rapid point-of-care (POC) tests that would be appropriate 
for use at community health care centres and which are cost-effective and sensitive, are 
developed. These POC tests should preferably be based on alternative sample types such as 
serum, saliva or urine, as tests based on sputum, including the existing microbiological tests, 
are not very suitable for use by individuals finding it difficult to provide decent quality sputum 
such as those with paediatric and extrapulmonary TB disease.  
 
Much work is currently being done in the search for new, immunodiagnostic approaches for 
active TB disease. Amongst the approaches currently being investigated are T cell based 
approaches, involving the isolation of peripheral blood mononuclear cells and staining for the 
expression of surface biomarkers by flow cytometry after overnight stimulation with M.tb 
antigens [71, 72], investigation of new M.tb infection phase dependent antigens [73], other 
than ESAT-6 and CFP-10 [74, 75], investigation of new biomarkers (other than IFN-γ) produced 
after overnight stimulation of blood cells with new M.tb antigens [76],RNA biosignatures [77], 
serodiagnostic assays evaluating antibodies against new M.tb antigens [78, 79] amongst 
others. A prototype of a POC test for the measurement of host biomarkers detected in 
biological fluids has already been developed and the utility of this prototype investigated  in 
several African countries [80].  
 
Despite the potential shown by these previous studies, diagnostic tests are likely to make the 
most impact on the control of TB disease if based on ex vivo host markers detected in 
unstimulated samples, such as would be obtained in easily accessible samples including serum 
or saliva.  Assays involving the use of these sample types would be more easily applicable for 
use at the POC especially in resource-limited settings. In previous antigen-stimulation studies 
by Chegou and colleagues,  it was observed that some host markers performed best either 
individually or in multi-marker models when measured in unstimulated supernatants [81]. 
These included interferon (IFN)-α2, Interferon inducible protein (IP)-10, tumour necrosis 
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factor (TNF)-α, epidermal growth factor (EGF), transforming growth factor (TGF)-α and 
vascular endothelial growth factor (VEGF) [81].  A recent large multi-centred study involving 
the detection of ex vivo host inflammatory biomarkers in serum samples, showed that a 
combination of seven host markers (C-reactive protein, transthyretin, IFN-γ, complement 
factor H, apolipoprotein-A1, inducible protein 10 and serum amyloid A) could diagnose TB 
disease with 93.8% sensitivity and 73.3% specificity[82]. Furthermore, studies done on saliva  
from individuals with symptoms suggestive of pulmonary TB disease also demonstrated that 
salivary host inflammatory biomarkers have potential as diagnostic candidates for TB disease 
[83–85]. Given the promise shown by these previous studies, there is hope that ex vivo host 
inflammatory biomarkers, including markers detectable in serum, plasma or saliva could be 
beneficial in the diagnosis of TB disease at the POC, therefore highlighting the need for further 
investigations into such diagnostic biosignatures.  
 
1.6 TB Treatment and Vaccines 
 
Drug susceptible TB requires a combination of multiple antibiotics, known as the ‘first line TB 
treatment regime’.  This approach recommends the administration of four first-line drugs 
during the intensive phase of treatment namely isoniazid (INH), ethambutol (EMB), rifampicin 
(RIF) and pyrazinamide (PZA) , after which the continuation phase follows, for a minimum 
total treatment duration of 6 months [86]. All four drugs are administered for the first 2 
months of treatment (in the intensive phase), followed by a further 4 months of treatment 
(continuation phase) with only INH and RIF. Directly observed therapy short course (DOTS) 
was implemented by WHO as a strategy to improve adherence due to the lengthy treatment 
of TB, and involves the directly observed administration of these drugs [87]. Despite the 
implementation of DOTS, MDR-TB still emerged, primarily due to non-compliance. MDR-TB is 
defined as resistance to INH and RIF. On the other hand, extremely drug resistant TB (XDR-
TB) is defined by resistance to second-line drugs (used to treat MDR TB), consisting of 
fluoroquinolones and aminoglycosides [88]. Treatment for the resistant forms of TB remains 
difficult and requires a longer course of treatment. Furthermore treatment success remains 
low for drug-resistant TB, with high rates of treatment failure and mortality reported 
worldwide, with even earlier mortality reported in individuals co-infected with HIV [9]. In 
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order to successfully eradicate TB, the development of an effective vaccine is needed. In 
countries with high burdens of TB or HIV, BCG vaccination was integrated into childhood 
immunization programs, where BCG is intradermally administered at, or shortly after birth 
[89]. BCG vaccination has been shown to provide some protection against more dangerous 
childhood forms of TB, however protection decreases by adolescences, for reasons that are 
not seemingly clear [90, 91]. Furthermore the efficacy of BCG seems to vary between 
population groups and it has been proposed that host genetic variability and socioeconomic 
factors might be contributing towards this differential efficacy [92]. The variability of BCG 
vaccination has led to the development of various new vaccines that are currently in clinical 
trials.  
 
1.6.1 Monitoring of the Response to TB Treatment 
 
Monitoring of the response to TB treatment remains a challenge, due to the lack of 
appropriate tools. In most settings, monitoring of TB treatment response entails repeating 
the sputum smear microscopy test at month 2 after treatment initiation [93]. Conversion from 
smear-positive to smear- negative after 2 months of treatment is currently the only accepted 
biomarker for TB treatment response [93]. The many well-established limitations of sputum 
smear microscopy are therefore also limitations of this treatment efficacy assessment 
strategy, besides the fact that sputum smear microscopy cannot discriminate between dead 
and live mycobacteria. Chest x-rays are also used to assess TB treatment response. However, 
this is not possible in resource-poor settings, and it is also difficult to standardize the 
assessment of x-rays [94]. The use of culture to monitor TB treatment response has yielded 
conflicting results and the availability and long turnaround time of culture also limits its use 
for this purpose [95, 96]. Additionally, the GeneXpert test is also not suitable to monitor the 
efficacy of treatment, as it is unable to distinguish between DNA from live and dead bacteria 
[97]. Therefore, tests for monitoring TB treatment response are urgently needed worldwide, 
both for individual patient benefits and for assessment of the efficacy of new drugs. Host 
immunological biomarkers have been shown to have potential as tools for monitoring of TB 
treatment response, including the prediction of month 2 smear and sputum status [98].  
However, no immunological tests currently exist for this purpose. In addition to the possibility 
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of easier incorporation into POC devices, host inflammatory biomarkers will be advantageous 
particularly if such tests are based on easily obtainable samples including serum, plasma or 
saliva. If measured early after the initiation of TB treatment, such biomarker based tests shall 
help in stratification of patients for standard or more intensive treatment. Therefore, there is 
a need for more work to be done on the identification of new biomarkers as well as validation 
of currently known potential candidates. Therefore in addition to the investigation of 
biomarkers as candidates for the diagnosis of TB disease, the utility of biomarkers as potential 
candidates for monitoring of TB treatment response was also assessed in the current thesis. 
Potential candidates could then be investigated further, in larger future cohort studies. 
 
1.7 Study Objectives 
 
1) To validate previously identified host biomarkers and to identify novel host biomarkers in 
plasma and saliva as diagnostic biosignatures for active TB disease 
 
2.) To investigate the potentials of host biomarkers detected in plasma and saliva as 
candidates for monitoring of the response to TB treatment 
 
3) To investigate a usefulness of antibodies against recently identified M.tb antigens as 
biomarkers for the diagnosis of active TB disease and monitoring of the response to TB 
treatment 
 
4) To investigate a diagnostic approach in which multiple classes of antibodies against M.tb 
antigens are combined with host inflammatory biomarkers (cytokines, chemokines and 
acute phase proteins amongst others) as a combined tool for the diagnosis of TB disease  
 




Materials and Methods 
 
2.1 Study Participants and Setting 
 
The individuals who provided samples for the studies presented in this thesis were recruited 
through a large European & Developing Countries Clinical Trials Partnership (EDCTP)-funded 
biomarker study (the African European Tuberculosis Consortium; www.ae-tbc.eu). This 
project was conducted at various field sites serving seven institutions situated in six other 
African countries, with five European partner institutions. These field sites were study sites 
for the Amauer Hansen Research Institute, Ethiopia, Ethiopian Health and Nutrition Research 
Institute, Addis Ababa, Ethiopia, Makerere University, Uganda, Karonga Prevention study, 
Malawi, MRC, The Gambia, The University of Namibia, Namibia and Stellenbosch University, 
South Africa. The study participants enrolled for the investigations presented in this thesis 
were recruited from the Fisantekraal Community Clinic in the outskirts of Cape Town, South 
Africa.  
 
All the study participants presented with signs and symptoms requiring investigation for 
pulmonary TB disease, and were recruited prior to any clinical or laboratory assessments. All 
study participants were recruited between November 2010 and November 2012. 
 
2.1.1 Inclusion Criteria 
 
Participants were enrolled if they presented with persistent cough lasting ≥2 weeks and at 
least one of the following: fever, malaise, recent weight loss, night sweats, knowledge of close 
contact with a TB patient, haemoptysis, chest pain or loss of appetite. Participants were 
eligible for the study if they were 18 years or older and willing to give written informed 
consent for participation in the study, including consent for HIV testing. 
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2.1.2 Exclusion Criteria 
 
Patients were excluded if they were pregnant, had not been residing in the study community 
for more than 3 months, were severely anaemic (haemoglobin <10 g/l), were on anti-TB 
treatment, had received anti-TB treatment in the previous 90 days or if they were on 
quinolone or aminoglycoside antibiotics during the past 60 days.  
 
2.1.3 Ethics Statement 
 
The study was approved by the Health Research Ethics Committee of the Faculty of Medicine 
and Health Sciences of the University of Stellenbosch (Reference no. N10/08/274). 
 
2.2 Sample Collection and Preparation 
 
In addition to providing samples that were used for routine diagnostic purposes, all the 
participants included in this thesis provided both plasma and saliva samples. Other samples 
including whole blood for serum separation, stimulation with different M.tb antigens and 
culturing, Quantiferon supernatants, urine, paxgene, DNA, peripheral blood mononuclear 
cells amongst others, were also collected from all study participants as required for the main 
study, for future studies. 
 
2.2.1 Plasma Sample Collection and Preparation 
 
Blood was collected  into 6ml heparinized BD vacutainer tubes (BD Biosciences, Franklin 
Lakes, NJ, USA) and transported to the laboratory at 4-8OC for further processing. Upon 
receipt in the laboratory, tubes were centrifuged at 2000 rpm for 10 minutes after which 
plasma was harvested, aliquoted and stored at -80 OC until used. Sample collection was 
repeated at months 2 and 6 after the start of TB treatment, only in individuals in whom TB 
disease was confirmed after diagnostic work-up. 
Stellenbosch University  https://scholar.sun.ac.za
15 
 
2.2.2 Saliva Sample Collection and Preparation 
 
Study participants fasted for at least one hour before saliva collection. Briefly, participants 
were asked to chew a sterile cotton swab (salivette) that was provided by the saliva collection 
kit manufacturer (Sarstedt, Numbrecht, Germany), for about 45 seconds. The swab was then 
removed from the participant’s mouth with sterile forceps, inserted into a sterile tube 
provided by the manufacturer, and then transported to the laboratory at 4 - 8oC. Upon arrival 
in the laboratory, the saliva samples were centrifuged at 1000g for 2 minutes and the 
supernatant harvested and stored at -80 oC until tested. After microbiological confirmation of 
TB disease in study participants, sample collection was repeated for the culture confirmed TB 
patients at month 2 and month 6 after the initiation of TB treatment. 
 
2.3 Reference Standard for Diagnosing TB Disease 
 
Routine diagnostic tests including mycobacterial cultures, sputum smears and chest 
radiography were performed on all study participants. Sputum samples were collected from 
all study participants and cultured using the Mycobacteria Growth Inhibitor Tube (MGIT) 
method (BD Biosciences, Franklin Lakes, NJ, USA). Positive MGIT cultures were examined for 
acid fast bacilli using the Ziehl-Neelsen technique (to check for contamination), followed by 
Capilia TB testing (TAUNS, Numazu, Japan), to confirm the isolation of organisms of the M.tb 
complex, before being designated as positive cultures. Sputum samples were also used to 
perform Ziehl- Neelsen sputum smear tests.  
 
By using a combination of clinical, radiological, and laboratory findings, participants were 
classified as definite TB patients, probable TB patients, questionable TB patients and 
participants with other respiratory diseases (ORD) as described in detail in table 2.1. 
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Table 2.1:  Case definitions used in classifying study participants (Reproduced from Chegou 
NN, et al. Thorax 2016) 
CXR, chest X-ray; M.tb, Mycobacterium tuberculosis; PTB, pulmonary TB. 
 
2.4 Luminex Multiplex Immunoassay 
 
The Bead-Based Luminex Multiplex Assay was used to determine the levels of 74 analytes in 
ex-vivo plasma and saliva samples from study participants. Briefly the Luminex Multiplex 
Immunoassay permits the quantitative simultaneous detection of a large array of soluble 
factors in a single sample (up to 500 biomarkers depending on the Luminex reader).  
 
This assay is based on bead sets fixed with different intensities of dyes and pre-coated with 
analyte-specific antibodies. These beads are examined by two lasers (as is the case with the 
Luminex 200 instruments), which identifies the spectral property of the beads and therefore 
the levels of the associated analyte. The 74 different analytes investigated in the current 
thesis were selected based on their potentials as TB diagnostic or treatment response 
biomarkers, as identified in previous studies. Additionally markers that have not previously 
been investigated in the TB field, but which have been studied in other diseases (for example 
in lung cancer) were also included as we thought it would be interesting to investigate their 
Classification Definition 
Definite TB Sputum culture positive for M.tb 
OR 
2 positive smears and symptoms responding to TB treatment 
OR 
1 Positive smear plus CXR suggestive of PTB 
Probable TB 1 positive smear and symptoms responding to TB treatment  
OR 




Positive smear(s), but no other supporting evidence 
OR 
CXR suggestive of PTB, but no other supporting evidence. 
OR 
Treatment initiated by healthcare providers on clinical suspicion 
only.  No other supporting evidence 
Other Respiratory 
Disease 
Negative cultures, negative smears, negative CXR and treatment 
never initiated by healthcare providers 
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potentials in both plasma and saliva samples in the context of TB disease. The experiments 
were performed using kits supplied by Merck Millipore, Billerica, MA, USA and Bio- Rad 
Laboratories, Hercules, CA, USA as indicated in table 2.2 below. Experiments were conducted 
according to the instructions of the different manufacturers (Merck Millipore or Bio-Rad), in 
96-well plates. However assay reagents for Luminex experiments were diluted 1:2 following 
the optimization experiments discussed in 2.8.1. 
 
Briefly, after the preparation of all the reagents, controls and standards (according to the 
manufacturer’s instructions) the standards, controls and samples were added to the 
appropriate wells, after which analyte-specific antibodies which were pre-coated onto color-
coded magnetic microspheres (beads), was added to each well. After 2 hour (at room 
temperature) or overnight (at 4oC) incubation on a shaker, depending on the type of kit, plates 
were washed using an automated magnetic bead washer (Bio-Rad). After addition of 
biotinylated detection antibodies, plates were incubated for 1 hour (for Milliplex kits or 30 
minutes for Bio-Rad kits) followed by a further wash step (kits from Bio Rad) and addition of 
streptavidin-pycoerythrin (streptavidin-PE). After 30 minutes incubation (10 minutes for kits 
from Bio-Rad), plates were washed, followed by resuspension of the beads on a shaker. Plates 
were read using either the Bio-Plex 200 system or Bio-Plex Magpix. All incubation steps were 
done with agitation on a shaker at room temperature (or 4oC) according to the speed 
recommended by the manufacturer. Beads were acquired and analysed using the Bio-Plex 
manager software, version 6.1 (Bio-Plex 200) or acquired using the Bio-Plex MP software, 
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Table 2.2: Kits and analytes used for Luminex Multiplex Immunoassay. Please see the list of 
abbreviations for the full names of the different host markers. Host markers are also defined 
after first use in chapters 3 and 4. 
Merck Millipore, 









Human CD8+ T-Cell  
Magnetic Bead Panel 
(HCD8MAG-15K-06) 




Bead Panel 1 
(HNDG1MAG-36K-05) 
APOA1, APOC3, Complement C3, Complement Factor H, 




Bead Panel 3  
(HNDG3MAG-36K-05) 




Magnetic Bead Panel 
(HCYTOMAG-60K-11) 
CD40L , IFN-G, IL-1B, TNF-A ,VEGF, IFN-A2, IL-12P40, IL-13, IP-10, 
MIP1B, TNFB 
Human TH17 
Magnetic Bead Panel ( 
HTH17MAG-14K-08) 




Bead Panel 2 
(HNDG2MAG-36K-
04)- 
α-2-Antitrypsin (A1AT), Complement C4, MIP4,PEDF 
Human 
Cytokine/Chemokine 
Magnetic Bead Panel 
III  (HCYP3MAG-63K-
06) 
LIX/CXCL6/GCP-2, IL-11, IL29, ITAC, MIG 
Human 
Cytokine/Chemokine 
Magnetic Bead Panel 
HCC1 







Magnetic Bead Panel 
2 (HCCBP2MAG-58K-
04) 
Antithrombin III, Extracellular Matrix Protein 1 (ECM1), Vitamin D 
Binding Protein, Vitronectin 
Human Cardiovascular 
Disease (CVD) 
Magnetic Bead Panel 
2  (HCVD2MAG-67K-
05)-      
ADAMTS13,GDF15,Myoglobin,NGAL/Lipocalin-2,sP-Selectin 
Human MMP 






Hercules, CA, USA) 
 
Human Acute Phase 
Multiplex 4 Plex Panel 
A2M, Haptoglobin, CRP, SAP 
Human Acute Phase 
Multiplex 5 Plex Panel 
PCT, Ferritin, TPA, Fibrinogen, SAA 
 
Prior to analysis, samples for HMMP2MAG-55K-02 were diluted 1:2, samples for HNDG3MAG-
36K-05, HCYP3MAG-63K-01, HCCBP2MAG-58K-04, HCVD2MAG-67K-05 and Human Acute 
Phase Multiplex 5 Plex Panel were diluted 1:100 , samples for HNDG2MAG-36K-04 were 
diluted 1:2000, while samples for HCCBP2MAG-58K-04 were diluted 1:10 000 and 
HNDG1MAG-36K-05 diluted 1:40 000, whereas those for HCYTOMAG-60K-11,HCYP2MAG-
62K-09,HCD8MAG-15K-06, HTH17MAG-14K-08, HCYP3MAG-63K-06 were evaluated neat 
(undiluted) following previous optimization experiments or recommendations from the 
manufacturer. 
 
2.5 Meso Scale Discovery (MSD) Assay 
 
The Meso Scale Discovery (MSD) platform is a relatively new platform that is being marketed 
as an alternative to the Luminex platform, for biomarker discovery purposes. Our laboratory 
recently acquired a MSD SQ120 instrument and as done for the optimization experiments 
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reported in 2.8.1, it was necessary for us to demonstrate that the equipment was fit-for-
purpose before introducing it for routine biomarker discovery and/or validation work in the 
laboratory. We therefore designed an experiment in which we compared the results obtained 
from the MSD platform to the well-established Luminex platforms (section 2.8.2). 
 
To investigate whether results generated by the two multiplex platforms currently used in our 
laboratory (Luminex and MSD) were comparable, plasma samples were similarly thawed, 
aliquoted and then analysed separately (same plasma samples on the different platforms). 
The Luminex kits containing the seven common analytes (CRP, SAA, IFN-γ, IL-1β, IL-13, TNF-α 
and MMP-9) were purchased from Merck Millipore and Bio-Rad as follows: CRP and SAA 
assays were purchased from Bio-Rad, whereas customized kits containing IFN-γ, IL-1β, IL-13, 
TNF-α and MMP-9 were purchased from Merck Millipore. All assays were performed 
according to the different manufacturers’ instructions (as described in section 2.4 for the 
Luminex platform). Experiment results are discussed in section 2.8.2. 
 
Briefly, MSD platform enables the detection and quantitation of biomarkers and signalling 
molecules in simple and complex matrices, by electrochemiluminescence detection, which 
uses labels that emit light (SULFO-TAG labels) when electrochemically stimulated. Each well 
in a MSD plate contains electrodes that are coated with capture antibodies, allowing the 
analyte to be captured on the electrode. Upon electrochemical stimulation, light emits at the 
surface of the electrode, therefore allowing the concentration of the analyte to be 
determined.  Background signals are believed to be minimal with this technology as the 
stimulation mechanism (electricity) is decoupled from the signal (light). Multiple cycles of 
each label amplify the signal to enhance light levels and improve sensitivity. The instruments 
use custom-designed optics and ultra-sensitive photo detectors to detect and quantitatively 
measure light emitted from the microplates after which electronic and signal processing 
algorithms convert the measured signal to useful data in real time (Figure 2.1). 














Figure 2.1: Principle of the Meso Scale Discovery technology as published by the company 
on https://www.mesoscale.com/en/technical_resources/our_technology/ecl. Biological 
reagents are attached to high binding carbon electrodes in the bottom of the MSD plates. The 
electrochemiluminescent labels employed in the assay (SULFO-TAG) are conjugated to 
detection antibodies, and allow for ultra-sensitive detection of analytes. After the MSD 
instrument applies electricity to the plate electrodes, the SULFO-TAG labels emit light, which 
is captured by an in-built camera. The intensity of the light emitted is proportional to the 
amount of analyte in the sample. Image downloaded from:  
https://www.mesoscale.com/en/technical_resources/our_technology/ecl 
 
MSD assays were performed as follows: after the preparation of reagents (according to the 
manufacturer’s instructions), samples, standards and controls were added to the appropriate 
wells in their respective 96-well plates and incubated for 2 hours at room temperature, with 
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agitation according to the speed recommended by the manufacturer. The plates were then 
washed 3 times with wash buffer after which detection antibody solution was added and 
incubated at room temperature with shaking for 2 hours. After incubation, the wash step was 
repeated after which 2X read buffer was added to each well and the plate read on the MSD 
QuickPlex SQ120 instrument. 
 
2.6 Enzyme-Linked Immunosorbent Assay 
 
The Enzyme-Linked Immunosorbent assay (ELISA) was used for the detection and quantitative 
determination of immunoglobulin (Ig) A, Ig G and Ig M antibodies against seven M.tb specific 
antigens (Table 2.3). Plasma samples were thawed and pre-diluted (1:5) with 87% glycerol 
and stored at -80 OC until needed for the ELISAs. On the day of the ELISA, the pre-diluted 
samples were further diluted (1:200) with sample diluent, following the optimization 
experiments described below (section 2.8.3). The experiments were performed according to 
manufacturer’s instructions (LIONEX Diagnostics and Therapeutics, Braunschweig, Germany). 
Briefly, after the preparation of reagents (according to the instructions of the manufacturer), 
diluted samples and standards were added to appropriate wells in 96-well plates containing 
immobilized purified recombinant antigens that were bound to the surface of the plates. After 
1 hour incubation at 37⁰C the plates were washed 3 times with diluted wash buffer. This was 
followed by the addition of the ready- to- use conjugate to each well and a further incubation 
for 30minutes at 37⁰C. After repeating the wash step, ready-to –use substrate solution was 
added to all wells, followed by incubation for 20 minutes at 37⁰C in the dark. The substrate 
reaction was terminated by the rapid addition of ready-to-use stop solution (5% H2SO4) into 
each well. The plate was then read on an ELISA plate reader (iMark™ Microplate absorbance 
reader, Bio-Rad, USA) by measuring the optical density at 450 nanometres (nm) and reference 
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Table 2.3: Recombinant antigens of M.tuberculosis used in the study 
M.tuberculosis 
antigens 
Mol mass (kDa) Rv number Ig Class 
EsxR (TB10.3) 36 Rv3019c IgA 
PstS1 37.37 Rv0934 IgA 
“Kit 1”      *      * IgA 
“Kit 2” * * IgA 
Apa 32.7 Rv1860 IgA 
NarL 23.9 Rv0844c IgA 
LAM - - IgM 
*Name of kits are not revealed due to intellectual property concerns with the manufacturer. 
Periplasmic phosphate-binding lipoprotein PstS1; Alanine and proline rich secreted protein 
Apa; Nitrate/nitrite response transcriptional regulatory protein NarL; lipoarabinomannan 
LAM , kDa kilo Dalton  
 
2.7 Statistical Analysis 
 
All statistical analyses were conducted using Statistica (Statsoft, Ohio, USA) and Graphpad 
Prism version 5 (Graphpad Software Inc., CA, USA). Differences between any two groups 
compared were analysed using the Mann-Whitney U test, if the data was not normally 
distributed, whereas the student’s t-test was used if the data was normally distributed. The 
diagnostic abilities of individual host markers and antibody responses for TB disease were 
assessed by receiver operator characteristics (ROC) curve analysis. Cut-off values that resulted 
in the highest combination of sensitivity and specificity were selected. The predictive abilities 
of combinations of host markers and/or antibodies were investigated by general discriminant 
analysis (GDA), with leave-one-out cross validation. Differences in the levels of host markers 
and antibodies during the course of TB treatment were analysed using mixed model repeated 
measures analysis of variance (ANOVA), with Fisher’s Least Significant Difference (LSD) post 
hoc testing. P-values ≤0.05 were considered significant. Statistical analyses were conducted 
with the assistance of a statistician from the Department of Statistics and Actuarial Sciences, 









2.8 Results of Optimization Experiments 
 
2.8.1 Optimization of Beads, Biotinylated Detection Antibodies and 
Streptavidin-phycoerithrin for use in Luminex Diluted Assays  
 
Dilution of reagents prior to usage in Luminex experiments is commonly performed in 
research laboratories worldwide, due to costs. As these protocols were introduced to our 
laboratory by our collaborators, there was a need to prove that assay reagents diluted as such 
still yielded the desired results, prior to implementation of the protocols in the laboratory. 
Therefore prior to performing the Luminex experiments described in the current thesis, the 
assay was optimized for the use of beads, streptavidin-PE and biotinylated detection 
antibodies with different dilutions that have been proposed by users in other laboratories. 
This reagent dilution optimization experiment was done using a Human Cytokine/Chemokine 
Magnetic Bead Panel III kit (HCYP-3MAG-63K-11), containing 11 analytes, purchased from 
Merck Millipore. Briefly, pooled plasma samples were used to perform the optimization 
experiment, with five different combinations of diluted reagents as shown in the table 2.4 
Experiment (“As recommended) was performed according to the recommendations of the 
manufacturer. 
 
Table 2.4: Experiment conditions used for the Luminex reagent dilution optimization 
experiment 
Experiment/Condition Beads Streptavidin-PE Detection Antibody 
1  As recommended As recommended As recommended 
2 1:2 Dilution 1:2 Dilution Undiluted (12.5μl) 
3 1:3 Dilution 1:3 Dilution Undiluted (12.5μl) 
4 1:3 Dilution 1:3 Dilution 1:2 Dilution (25μl) 










There were significant differences between experiments 3 to 6 and the manufacturers 
recommended assay conditions (experiment 1) (Figure 2.2). As there was no significant 
difference between the manufacturer’s recommendation (experiment 1) and experiment 2 
(dilution of all reagents by 2), experiment 2 was used for all the Luminex experiments 
presented in this thesis. It is important to note that all quality control reagents yielded the 
required results when evaluated on kits using experiment 2 procedure. Implementation of 











































Figure 2.2: Optimization results comparing the different Luminex reagent dilution 
conditions. Differences between experiment 1 (recommended condition) and all the other 
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2.8.2 Comparison of the Concentrations of Biomarkers Detected by the 
Luminex and Meso Scale Discovery Platforms 
 
The two Luminex equipment in our laboratory (the Bio-Plex 200 system and Bio- Plex Magpix) 
are well established platforms that have been used for biomarker research in our group for 
several years. In addition to correlating with each other, results obtained with either of the 
Luminex instruments compare excellently with results generated from the same samples 
using different Luminex instruments in different laboratories all over the world. These 
findings are the result of the laboratory’s ongoing participation in a Luminex External Quality 
Assurance Program (EQAPOL) which is coordinated by Duke University Vaccine Institute, with 
funding from the National Institutes of Health (NIH).  
The Meso Scale Discovery (MSD) platform is a new platform that was recently acquired by our 
laboratory. As the MSD platform is a relatively new platform in the field of biomarker 
discovery, not much information is yet available in literature on the platform and no External 
Quality Assurance (EQA) scheme currently exists, that makes use of the platform. While 
analysing the plasma samples investigated in chapter 3 using the Luminex technology, we 
simultaneously investigated the levels of some of the biomarkers using the MSD platform. We 
therefore aimed to compare the results obtained from the established Luminex platform with 
results obtained from the MSD platform, in order to demonstrate that the new platform 
(MSD) was fit for purpose. We therefore hypothesized that although the absolute 
concentrations may not be the same, there was excellent correlation between cytokine 
measurements detected by the two platforms, which would enable usage of the MSD 
platform in future biomarker discovery and/or validation experiments.  
Prior to the commencement of the experiments, plasma samples from all study participants 
were thawed on ice, aliquoted and re-frozen at -80OC. On the date of the experiments, 
aliquots reserved for the different platforms (MSD or Luminex) were thawed, followed by the 
performance of experiments as recommended by the different manufacturers (Merck 
Millipore, for Luminex kits, and MSD for MSD assays) and reading on the different platforms 
following the settings recommended by the different manufacturers. We therefore compared 
the levels of seven proteins namely; CRP, SAA, IFN-γ, IL-1β, IL-13, TNF-α and MMP- 9 that 
were available for the two platforms.  





The descriptive statistical data obtained after comparing cytokine levels detected using the 




























































70 70 70 70 70 70 70 70 70 70 70 70 70 70 
Minimum 0.0000 0.0000 0.0000 0.1373 0.6100 0.6820 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 160400 36.02 
25% 
Percentile 
1683 411.3 2627 1010 6.590 2.447 2.713 11.03 0.0000 0.01619 0.0000 0.5422 324800 101000 
Median 4549 1438 8305 1462 11.98 3.285 14.82 21.63 1.815 0.07432 0.0000 0.9620 484100 181700 
75% 
Percentile 
18140 2704 23140 1773 22.25 5.028 79.26 99.43 8.228 0.3347 9.990 1.740 707700 310600 
Maximum 290300 124200 43000 2453 414.6 302.8 660.5 869.1 239.6 16.77 1251 15.70 266200
0 
931400 
Mean 30220 4981 14470 1367 23.13 12.58 91.32 102.5 15.66 0.6421 54.61 1.433 606600 233100 
Std. 
Deviation 
59790 16810 15650 474.6 51.27 48.79 167.7 174.4 42.49 2.287 178.2 2.089 463600 185200 
Std. Error 7146 2009 1871 56.73 6.128 5.831 20.05 20.85 5.078 0.2733 21.30 0.2497 55410 22140 
Lower 95% 
CI 
15960 972.7 10740 1254 10.90 0.9470 51.32 60.95 5.530 0.09686 12.11 0.9351 496000 189000 
Upper 95% 
CI 
44470 8989 18200 1480 35.35 24.21 131.3 144.1 25.79 1.187 97.10 1.931 717100 277300 
pg/ml, pico grams per millilitre ,ng/ml, nano grams per millilitre, Std Standard Deviation ,  CI ,Confidence Interval    
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We later evaluated the correlation between pairs of values obtained for each of the seven 
proteins using the Spearman correlation coefficient. Out of the seven host markers evaluated, 
only three (SAA, TNF-α and MMP-9) correlated well between the two platforms. Before and 
after graphs mapping the value obtained for each protein using the Luminex platform to the 










Figure 2.3: Before and after graphs showing the concentration of each analyte as 
measured by each instrument. The concentration of each analyte obtained from the 
Luminex instrument was mapped to the concentration of the same analyte in the same 
sample, as measured by the MSD instrument. The p-values in the before and after graphs 
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were calculated using the Mann Whitney U test whereas Spearman correlation coefficients 
and p-values are shown in the correlation graphs. 
 
2.8.2.2: Discussion and Conclusion 
 
It was not expected that the magnitude of responses detected by the two assays would be 
the same. However, it was expected that there would be an excellent correlation between 
the two platforms. Our data shows that results obtained between the two platforms do not 
correlate well, at least for the biomarkers investigated, in plasma samples. Therefore the 
implications are that if planning to use the MSD platform in future experiments, pilot 
experiments should be done prior to large experiments to ascertain if the markers of interest 
correlate with other well established platforms. It must be stressed that after completion of 
these experiments, the results were discussed with the manufacturer of the MSD platform, 
who evaluated the raw data, including data for standards and controls and confirmed that 
the results were valid. There reasons for the differences between the two platforms are not 
clear. However, the observed differences might be due to the different antibody epitopes or 
splice variants being measured in the kits supplied by the two companies. There is therefore 
a need for further investigation of the observed differences between the two platforms. As 
the Luminex platform is well-established and has been shown to correlate well with ELISA in 
experiments performed in our laboratory, and other laboratories worldwide, this platform 
was chosen for use in all the biomarker discovery experiments reported in this thesis. 
 
2.8.3 ELISA Optimization Experiment 
 
Prior to performing the ELISA experiments reported in Chapter 5, the kits were optimized for 
different sample dilutions and volumes. As the ELISA kit employed in the study were relatively 
new kits, which were still under development by the manufacturer, who was a collaborator 
on the project. Therefore it was deemed necessary that the assay be optimized, prior to use 
on the samples used in the study. The sample dilution and amount of sample used in the ELISA 
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experiments were therefore optimized prior to performing the required experiments as 
follows: 
 
 Samples from four TB patients and four latently infected individuals (as defined by a positive 
QuantiFERON in Tube test result) were evaluated on each optimization plate. Samples were 
pre-diluted (1:5) in glycerol and frozen at -80oC. On the day of the optimization experiment, 
samples were thawed and either further diluted 1:200 or 1:100 (in assay buffer), followed by 
the addition of 100μl or 200μl into the assay plate as shown in the plate layout below. 
Optimization experiments were done for Ig A and/or Ig G kits coated with “Kit 1”, “Kit 2”, LAM 
and thiol peroxidase (TpX) antigens. 
 
 
Figure 2.4: Layout for ELISA optimization experiment showing the dilution of samples and 
the amount of each diluted sample added to the optimization plate. Four TB and four 
latently infected individuals were used for the optimization experiments. Each sample was 
added in duplicate for each dilution (1:100/1:200) and each sample volume (100μl/200μl). 
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2.8.3.1 Results and Conclusion 
 
There were no significant differences between the results obtained with the different dilution 
experiment conditions (Figure 2.5). All the subsequent ELISA experiments conducted in this 
thesis were performed using the manufacturer’s recommended dilution conditions (1:200 

















































Figure 2.5: ELISA optimization results. The OD450nm values are shown when the data generated 
from individuals with TB and LTBI was combined and OD450nm values for TB and LTBI individuals 
were analysed separately. Differences between the recommended sample dilution and 
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volume (1:200 and 100μl) and all the other dilutions and volumes were analysed using the 
Mann-Whitney U test. 
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Tuberculosis (TB) disease, although curable, still accounted for the deaths of 1.5 million 
people in 2014 [9]. Rapid and accurate tools are urgently needed for early diagnosis of the 
disease, and monitoring of the response to treatment. The gold standard test for TB (culture) 
is not widely available, especially in resource-poor settings. The Ziehl-Neelsen sputum smear 
test is often the only available diagnostic tool in these settings, even though its limitations are 
well publicised [59]. Month 2 culture conversion is the most investigated biomarker for TB 
treatment response, but the wide unavailability of culture and its long turn-around time are 
serious limitations. Smear microscopy is not very useful for monitoring anti-TB treatment 
response as it is unable to distinguish live from dead bacilli [99]. The development of the 
geneXpert MTB/RIF test (Cepheid Inc., Sunnyvale, USA) was a significant advance in the TB 
diagnostic field as the test yields results within 2 hours, coupled with the detection of 
resistance to rifampicin, as a proxy for multi-drug resistant TB [63]. The high operating costs 
and need for infrastructure are amongst the major obstacles for its implementation in 
resource-poor settings. The geneXpert test is also not useful in monitoring of TB treatment 
response as the test cannot distinguish between DNA from dead and live bacteria [97]. 
Immunodiagnostic techniques may be useful in both the diagnosis of TB disease and 
monitoring of the response to treatment, especially as they may be easily adaptable into 
rapid, point-of-care tests, which would be suitable in resource-constrained settings. 
Furthermore, such tests will also be beneficial in cases where a conventional sputum-based 
diagnosis (smear microscopy, culture or geneXpert) is difficult e.g. in paediatric TB and in 
individuals with extrapulmonary TB. 
 
IFN-gamma (IFN-γ) release assays (IGRA) remain the most widely used commercial 
immunodiagnostic tests for TB. These assays have been shown to be useful in the diagnosis 
of infection with Mycobacterium tuberculosis (M.tb) but as they cannot discriminate between 
active TB disease and latent M.tb infection, they are of limited value in high TB-endemic areas. 
The use of IGRAs as tools for monitoring of the response to TB treatment has so far yielded 
conflicting results [96,95]. An important limitation of overnight culture-based assays such as 
IGRAs is the fact that they are not suitable as point-of-care tests. These tests are therefore 
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not ideal for resource-constrained settings. The potential value of diagnostic approaches that 
are based on the detection of host biomarkers ex vivo, in easily obtainable samples such as 
saliva, serum or plasma has been demonstrated in previous studies [82–84, 100]. Such host 
biomarker based tests in addition to being used as diagnostic tests for TB, may also be useful 
in monitoring of the response to TB treatment [83,98,101]. Despite the promise so far shown 
in these previous investigations, no validated diagnostic tests based on the detection of host 
biomarkers in unstimulated samples currently exist. It is therefore important to validate the 
potential biomarkers that have so far been identified, and also identify new candidate host 
markers that might be useful in conjunction with previously identified biosignatures, in the 
diagnosis of TB disease. 
 
In the present study, we investigated multiple host markers, including previously identified 
promising host markers, and relatively new markers, some of which have not previously been 
investigated in the TB field, as candidates for the immunological diagnosis of TB disease and 
monitoring of the response to TB treatment.  
 
3.2 Materials and Methods 
 
3.2.1 Study Participants 
 
As discussed in chapter 2 (section 2.1),participants enrolled into the present study were 
individuals who presented with signs and symptoms requiring investigation for TB disease at 
the Fisantekraal Community Clinic in the outskirts of Cape Town, South Africa.  The study was 
a sub-study of a larger diagnostic biomarker project (the African European Tuberculosis 
Consortium), that was ongoing at the study site and at field sites situated in six other African 
countries (www.ae-tbc.eu). All study participants presented with persistent cough lasting ≥2 
weeks and at least one of either fever, malaise, recent weight loss, night sweats, knowledge 
of close contact with a TB patient, haemoptysis, chest pain or loss of appetite. Participants 
were eligible for the study if they were 18 years or older and willing to give written informed 
consent for participation in the study, including consent for HIV testing. Patients were 
excluded if they were pregnant, had not been residing in the study community for more than 
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3 months, were severely anaemic (haemoglobin <10 g/l), were on anti-TB treatment, had 
received anti-TB treatment in the previous 90 days or if they were on quinolone or 
aminoglycoside antibiotics during the past 60 days. The study was approved by the Health 
Research Ethics Committee of the Faculty of Medicine and Health Sciences of the University 
of Stellenbosch. 
 
3.2.2 Sample Collection and Diagnostic Tests 
 
As discussed in Chapter 2 (section 2.2.1), 6ml of blood was collected at enrolment into 
heparinized BD vacutainer tubes (BD Biosciences, Franklin Lakes, NJ, USA) and transported to 
the laboratory at 4-8OC for further processing. Upon receipt in the laboratory, tubes were 
centrifuged at 2000 rpm for 10 minutes after which plasma was harvested, aliquoted and 
stored at -80 OC until analysed. As discussed in chapter 2 (section 2.3), sputum samples were 
collected from all study participants and cultured using the MGIT method (BD Biosciences). 
Positive MGIT cultures were examined for acid fast bacilli using the Ziehl-Neelsen technique 
(to check for contamination), followed by Capilia TB testing (TAUNS, Numazu, Japan), to 
confirm the isolation of organisms of the M.tb complex, before being designated as positive 
cultures.  
 
3.2.3 Classification of Study Participants and Reference Standard 
 
As previously described in chapter 2 (section 2.3), participants were classified as definite TB 
cases, probable TB cases, participants with other respiratory diseases (ORD) or questionable 
disease status using a combination of clinical, radiological, and laboratory findings [83]. 
However, only definite TB cases (culture positive individuals) and those with ORD were 
included in this discovery study. Briefly, individuals with ORD had a range of other diagnoses, 
including upper and lower respiratory tract infections (viral and bacterial infections, although 
attempts to identify organisms by bacterial or viral cultures were not made), and acute 
exacerbations of chronic obstructive pulmonary disease or asthma. Because of the 
disproportionately high number of individuals with ORD, we included all the 22 culture 
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positive TB cases that were available at the study site and randomly selected 33 individuals 
with ORD from the study biobank, for inclusion into the current study.   
 
3.2.4 Luminex Multiplex Immunoassay 
 
The concentrations of 74 host markers including alpha-2-macroglobulin (A2M) , haptoglobin, 
C-reactive protein (CRP), serum amyloid P (SAP), procalcitonin (PCT), ferritin, tissue 
plasminogen activator (TPA), fibrinogen, serum amyloid A (SAA) (kits purchased from Bio-Rad 
Laboratories, Hercules, CA, USA), vitronectin, extracellular matrix protein 1 (ECM1), 
antithrombin III, vitamin D binding protein (VDBP), sFas,  granzyme A, sFasL, sCD137, 
granzyme B, perforin, myoglobulin, ADAMTS13, P-selectin, lipocalin-2, growth differentiation 
factor (GDF) -15 , thrombopoietin (TPO), stem cell factor (SCF), B-cell attracting chemokine 
(BCA)-1, epithelial neutrophil activating protein (ENA-78), thymic stromal lymphopoietin 
(TSLP), I-309(CCL-1), stromal cell derived factor-1 alpha (SDF-1α), IFN-γ, IFN-α2, interferon 
gamma inducible protein (IP)-10 (CXCL10), macrophage inflammatory protein (MIP)-1β, 
tumor necrosis factor (TNF)-α, TNF-β, vascular endothelial growth factor (VEGF), soluble CD40 
ligand (sCD40L), apolipoprotein (Apo) A-1, Apo CIII, complement component 3 (CC3), 
transthyretin, complement factor H (CFH), total plasminogen activator inhibitor-1 (PAI-1), 
neural cell adhesion molecule (NCAM), brain-derived neurotrophic factor (BDNF), cathepsin 
D, myeloperoxidase (MPO),  matrix metalloproteinase (MMP)-2, MMP-9, monokine induced 
by gamma interferon (MIG/CXCL9), granulocyte chemotactic protein-2 (GCP2), interferon 
inducible T-cell alpha chemoattractant (I-TAC/CXCL11), hemofiltrate CC chemokine-1 (HCC1), 
α1-antitrypsin, pigment epithelium derived factor (PEDF), macrophage inflammatory protein-
4 (MIP-4/CCL18), complement C4, interleukin  (IL)-17F, IL-17A, IL-22, IL-33, IL-21, IL-23, IL-25, 
IL-31, IL-28A, IL-16, IL-1β, IL-12(p40), IL-13, IL-11 and IL-29 (kits purchased from Merck 
Millipore, Billerica, MA, USA), were investigated in plasma samples from all the study 
participants. The experiments were performed blindly, according to the instructions of the kit 
manufacturers, on the Bio-Plex platform (Bio-Rad). The Bio-Plex manager Software version 
6.1 was used for bead acquisition and analysis of median fluorescence intensities. 
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3.2.5 Statistical Analysis 
 
As discussed in chapter 2 (section 2.7), differences in the concentrations of host markers 
between TB patients and individuals with ORD were analysed using the Mann-Whitney U test. 
The diagnostic abilities of individual host markers were assessed by receiver operator 
characteristics (ROC) curve analysis. Optimal cut-off values and associated sensitivity and 
specificity were determined based on the Youden’s Index [102]. The predictive abilities of 
combinations of host markers were investigated by general discriminant analysis (GDA), with 
leave-one-out cross validation [103]. Differences in the expression profiles of host markers 
during the course of TB treatment were analysed using mixed model repeated measures 
analysis of variance (ANOVA), with Fisher’s Least Significant Difference (LSD) post hoc testing. 
P-values ≤0.05 were considered significant. The data were analysed using Statistica (Statsoft, 




A total of 55 study participants, 22 of whom were culture positive TB patients were 
investigated in this study. The mean age of all study participants was 35.8 ± 10.2 years and 14 
(25%) were HIV infected. The clinical and demographic characteristics of study participants 
are shown in table 3.1. 
Table 3.1: Clinical and demographic characteristics of study participants. All the 22 TB 









Males, n (%) 22 (40) 7 (32) 15 (45) 
Mean age, 
(Years)±SD 
35.8 ± 10.2  38.8 ±10.1 33.9 ± 9.9 
HIV Infected, n(%)  14(25) 4(18) 10(30) 
Quantiferon results    
Positive, n (%) 34 (64) 15 (75) 19 (58) 
Negative, n (%) 18 (34) 4 (20) 14 (42) 
Indeterminate, n (%) 1 (2) 1 (5) 0 (0) 
Abbreviations: TB= pulmonary tuberculosis, SD=standard deviation  
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3.3.1 Utility of individual host markers in the diagnosis of TB disease 
 
When the baseline concentrations of host markers in TB patients (n=22) were compared to 
the levels detected in patients with ORD (n=33), by the Mann Whitney U test, the 
concentrations of 23 out of the 74 analytes were significantly different between the two 
groups. The median levels of CRP, SAP, PCT, ferritin, TPA, SAA, ADAMTS-13, p-selectin, GDF-
15, I-309, IFN-γ, IP-10, TNF-α, CFH, MIG, ITAC, HCC-1 and MIP-4 were significantly higher in 
TB cases, whereas the levels of antithrombin III, Apo A-1, transthyretin, NCAM and BDNF were 
significantly higher in the ORD group. Trends (0.05<p ≤ 0.01) towards higher levels of sFas, 
lipocalin-2, VEGF, PEDF, CC4 and IL-33 were observed in TB cases (Table 3.2). When the 
diagnostic accuracies of individual host markers were investigated by ROC curve analysis, the 
area under the ROC curve (AUC) was ≥0.70 for 18 markers (Table 3.2). The most accurate 
single host markers included CRP, SAP, NCAM, TPA, I-309, and MIG, which all performed with 
AUC ≥ 0.80 (Table 3.2). Representative plots showing some of the most accurate individual 
host markers are shown in Figure 3.1. When data was stratified according to HIV infection 
status, concentrations of three additional markers (A2M, MIP-1β and VEGF) became 
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Table 3.2: Median levels (and inter-quartile ranges in parenthesis) of host biomarkers 
detected in baseline plasma samples from pulmonary TB patients (n=22) and individuals 
with other respiratory diseases (n=33) and their diagnostic accuracies for TB disease. Only 
analytes showing significant differences or trends between groups with the Mann-Whitney U 
test are shown. Optimal cut-off values and associated sensitivity and specificity were 
determined based on the Youden’s Index. The concentrations of CRP, SAP, SAA, antithrombin 
III, ADAMTS-13, p-selectin, GDF-15, Apo A-1, transthyretin, CFH, sFAS, lipocalin-2, MIP-4 and 
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Figure 3.1: Concentrations of host markers detected in plasma samples from TB patients 
(n=22) and individuals with other respiratory diseases (n=33) and receiver operator 
characteristics curves showing the accuracies of these markers in the diagnosis of TB 
disease. Representative plots are shown for CRP, SAP, ferritin, IP-10, NCAM and MIG. Error 
bars in the scatter dot plots represent the median with interquartile range. 
3.3.2 Utility of Multi-Plasma Marker Biosignatures in the Diagnosis of TB 
Disease 
 
When the data obtained from all the TB patients and those with ORD were fitted into General 
Discriminant Analysis (GDA) models regardless of HIV status, combinations between up to six 
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different host markers showed potential in the diagnosis of TB disease. A five-marker 
biosignature comprising of NCAM, SAP, ferritin, CFH and ECM-1 diagnosed TB disease with a 
sensitivity of 95.2% (95% CI, 81.0-99.9%) and specificity of 92.9% (95% CI, 70.8-98.9%) in the 
resubstitution classification matrix and sensitivity of 95.2% (95% CI, 81.0-99.9%) and 
specificity of 89.3% (95% CI, 66.4-97.2%) after leave-one-out cross validation. However, the 
most optimal diagnostic biosignature irrespective of HIV status was a combination between 
six markers (NCAM, SAP, IL-1β, sCD40L, IL-13 and Apo A-1), which diagnosed TB disease with 
a sensitivity 100% (95% CI, 86.3-100%) and specificity of 89.3% (95%CI, 67.6-97.3%) after 
leave-one-out cross validation. The positive and negative predictive values of the six-marker 
biosignature were 87.5% (95% CI, 66.5-96.7%) and 100% (95%CI, 83.4-100%) respectively 
(Figure 3.2, Table 3.3). 
 
When the GDA procedure was repeated after excluding the HIV infected individuals, two six-
marker biosignatures:- NCAM, A2M, IL-22, ferritin, myoglobulin and IL-12(p40), and NCAM, 
A2M, IL-22, ferritin, TNF-β and MIP-4, diagnosed TB disease with both sensitivity and 
specificity of 100% (AUC = 1.0, 95% CI, 1.0-1.0) (Table 3.3). NCAM was the most frequent 
analyte in biosignatures, appearing in all the top 13 biosignatures for diagnosing TB disease 
regardless of HIV infection status, and in 68%(23 of the 34) biosignatures that were generated 
for the diagnosis of TB disease after excluding HIV infected individuals. Other markers that 
occurred most frequently in diagnostic biosignatures for TB disease included GDF-15, SAP, 
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Table 3.3: Accuracies of plasma protein biosignatures in the diagnosis of TB disease. Only 
the top two biosignatures generated for the diagnosis of TB disease, regardless of HIV 
infection status and in the HIV uninfected individuals only, are shown. The importance of 
the different analytes in biosignatures for the diagnosis of TB disease is shown in Figure 3.2. 











































































































































Figure 3.2: Accuracy of multi-marker models in the diagnosis of TB disease. Receiver 
operator characteristics (ROC) curve showing the accuracy of the most accurate six-marker 
biosignature (NCAM, SAP, IL-1β, sCD40L, IL-13 and Apo A-1) in the diagnosis of TB disease in 
all study participants, regardless of HIV infection status (A), frequency of analytes in the top 
13 general discriminant analysis (GDA) models that most accurately classified study 
participants as TB disease or ORD irrespective of HIV status (B), ROC curve showing the 
accuracy of the most accurate six-marker biosignature (NCAM+A2M+IL-22+ferritin+ 
myoglobulin+IL-12(p40) or NCAM+A2M+IL-22+ferritin+TNF-β+MIP-4)  in the diagnosis of TB 
disease in HIV negative study participants (C), and frequency of analytes in the top 34 GDA 
models that most accurately classified study participants as TB disease or ORD in the absence 
of HIV infection (D). The bar graphs (B and D) indicate the frequency of analytes in the most 
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3.3.3 Changes in Host Biomarker Levels during the Course of TB Treatment 
 
To investigate whether any of the 74 host markers could potentially be used to monitor the 
response to TB treatment, the host markers were evaluated in plasma samples that were 
collected from TB patients at the end of standard TB treatment (month 6). Of the 22 TB 
patients that were investigated in this study however, only 15 (68%) returned to the clinic and 
provided samples at the end of treatment. Compared to baseline levels, the concentrations 
of 11 host markers changed significantly during the course of treatment. There was a 
significant decrease in the levels of CRP, SAP, ferritin, IFN-γ, VEGF, IP-10, CC3, CFH and α-1-
antitrypsin from baseline to month 6, whereas a significant increase in the levels of 
transthyretin and MMP-2 was observed. The levels of IL-1β, SAA, sFas and MIG showed trends 
towards decreasing levels from baseline to month 6, whereas Apo-CIII, Apo A-1 and GCP-2 
showed trends towards increasing levels at the end of treatment (Figure 3.3). 





Figure 3.3: Before (baseline) and after treatment (month 6) concentrations of host markers 
in plasma samples from TB patients. Plasma was collected from patients at recruitment, prior 
to the initiation of anti-TB therapy and then at the end of standard TB treatment (month 6). 




We investigated the diagnostic potentials of 74 host markers in plasma samples that were 
obtained from confirmed active TB cases and individuals with ORD, as candidates for the 
diagnosis of TB disease. Although 18 of the 74 host markers including relatively new 
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biomarkers in the TB field namely; antithrombin III, GDF-15, NCAM, HCC1, MIP-4 and recently 
identified markers I-309, MIG, Apo A-1, transthyretin and CFH, showed potential in the 
diagnosis of TB disease, regardless of HIV infection status as determined by area under the 
ROC curve (AUC), the most optimal diagnostic biosignature irrespective of HIV infection status 
was a six-marker model comprising of NCAM, SAP, IL-1β, sCD40L, IL-13 and Apo A-1, which 
diagnosed TB disease with a sensitivity of 100% and specificity of 89.3%, with promising 
positive and negative predictive values. In the absence of HIV infection, six-marker 
biosignatures diagnosed TB disease with 100% accuracy.  
 
Amongst the 18 host markers that showed the most potential in the diagnosis of TB disease 
individually as determined by AUC, six (CRP, SAP, PCT, ferritin, TPA and SAA) were acute phase 
proteins, five (I-309, MIP-4, Apo A-1, transthyretin and CFH) were markers that play various 
roles in the body and  have recently been identified as promising TB diagnostic candidates 
[104,82], two (TNF-α and IP-10) are widely investigated TB biomarkers [105] whereas four 
(antithrombin III, GDF-15, NCAM, HCC1), were relatively new markers, which have not 
previously been investigated in the TB field. Other host markers including ECM-1, IL-1β, 
sCD40L and IL-13 although not very promising individually in the current study, were included 
into the top diagnostic biosignatures for TB disease.  
 
Acute phase proteins are primarily produced by the liver, and act as opsonins at inflammatory 
sites [106]. Serum CRP has been extensively studied and shown to be promising for both the 
diagnosis of TB disease and monitoring of TB treatment response [107,108]. SAP, a 
homologue of CRP,  has also been shown to have a protective role against bacterial infections 
[109]. Ferritin is a well-recognised protein in iron storage processes. It has long been 
established that iron acquisition is an essential virulence mechanism for pathogenic bacteria 
[110,111]. The concentrations of all the acute phase proteins that showed potential in the 
current study were elevated in the TB patients, and this is in agreement with previous findings 
[111,82,112].   
 
The chemokines; MIG(CXCL9), IP-10(CXCL10),  ITAC(CXCL11) and I-309(CCL-1) are found in 
abundance in activated bronchial epithelium [113]. MIP-4(CCL18) is a chemokine that is 
produced mainly by antigen presenting cells [114]. These chemokines play vital roles in the 
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recruitment of activated T-cells to the site of infection [113][115]. Our finding of significantly 
higher levels of these chemokines in the plasma of patients with active TB is in agreement 
with previous observations [104,116,117,114]. The relatively new host markers investigated 
in the study (GDF-15, antithrombin III, HCC1 and NCAM) showed potential individually, in the 
diagnosis of TB disease. Other markers including p-selectin, ADAMTS-13 and BDNF although 
not amongst the most promising single markers as demonstrated by ROC curve analysis, were 
significantly different between the TB patients and individuals with ORD, with the Mann-
Whitney U test. GDF-15 is a member of the transforming growth factor beta superfamily (TGF-
β) and its expression is associated with tissue damage, but has also been reported to exhibit 
tissue protective functions [118,119]. It has been identified as a prognostic marker for 
prostate cancer, with high serum levels observed in patients with liver cirrhosis and 
hepatocellular carcinoma [120,121]. Antithrombin complexes are important mediators of the 
coagulation system, with antithrombin III being  one of the most important inhibitors of this 
system [122]. Markedly lowered antithrombin III plasma levels have been observed in sepsis 
[123]. HCC1 has been identified as a monocyte chemoattractant, with high concentrations 
observed in patients with chronic renal failure [124]. P-selectin is part of the selectin family 
of cell adhesion molecules, that promotes inflammatory reactions [125]. ADAMTS-13 is a 
metalloprotease with thrombospondin repeats, and has shown low activity in patients with 
recurrent thrombaotic thrombocytopenic purpura [126,127]. In a previous study by Liu et al, 
GDF-15 levels were not significantly different between TB patients, latently infected 
individuals and healthy controls [121]. However, GDF-15 levels showed potential in the 
current study. In agreement with the findings of the current study, Mukae et al observed 
significantly higher levels of p-selectin in TB patients in comparison to individuals with ORD 
[128]. For the other newly identified TB diagnostic candidates, we observed higher levels of 
HCC1 and ADAMTS-13 in TB patients, but the levels of antithrombin III and NCAM were higher 
in individuals with ORD.   
 
NCAM (CD56) is important in cell-cell or cell-matrix interactions, and is involved in neuronal 
differentiation, branching and survival [129]. It has been shown to play a role in lung tumor 
progression [130]. In the present study, we demonstrate for the first time, the potential of 
NCAM as a biomarker for TB disease. NCAM was the most frequently occurring marker in 
biosignatures for the diagnosis of TB disease, and was included in all the top 13 marker 
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combinations for the diagnosis of TB disease regardless of HIV infection status, and in 68% of 
the models that were generated when HIV infected individuals were excluded. The 
combination of NCAM with five other markers (SAP, IL-1β, sCD40L, IL-13 and Apo A-1), 
diagnosed TB disease regardless of HIV infection status, with high accuracy, whereas all the 
TB patients and individuals with ORD were accurately classified (100% sensitivity and 
specificity) when NCAM was used in combination with either A2M+IL-
22+ferritin+myoglobulin+IL-12(p40), or A2M+IL-22+ferritin+TNF-β+MIP-4, in the absence of 
HIV infection. In our previous serum-based study [82], optimal diagnosis of TB disease was 
achieved using a seven-marker biosignature of CRP, IFN-γ, IP-10, Apo A-1, transthyretin, SAA 
and CFH.  While our previous study was conducted on 716 participants that were recruited 
from five different African countries, the current study was conducted on 55 individuals who 
were recruited at a single study site, and analysis was performed on plasma and not serum 
samples. There was excellent agreement between the findings of this and the serum study, 
as the diagnostic potential observed for individual host markers including CRP, SAA, SAP, CFH, 
Apo A-1, transthyretin, ferritin amongst others, was replicated in the current study. This 
implies that the new host markers identified in this study may be used in conjunction with, or 
as alternatives to the markers that were included in the previous seven-marker biosignature 
[82] if a point-of-care screening test based on these biosignatures were to be developed. 
However, further studies are required to determine the best combination of analytes before 
such a screening test can be developed. 
  
In addition to being potentially useful as diagnostic candidates for TB disease, 11 of the 
markers investigated including CRP, SAP, ferritin, IP-10, α-1-antitrypsin changed with 
treatment, thereby indicating that they may be potential candidates for monitoring of the 
response to TB treatment. Although our observations for MMP-2 (increasing levels from 
baseline to month 6) were contrary to the observations of  Ugarte-Gil et al (decreasing levels 
from baseline to month 6 in sputum culture positive individuals after 2 weeks of treatment) 
[131], our observations for CRP, SAP, ferritin, IP-10, and α-1-antitrypsin are in agreement with 
findings from previous studies [132,133]. More studies are required to validate the potential 
of these biomarkers, and investigate whether any of the markers would be able to distinguish 
between clinical cure, treatment failure and relapse. Furthermore, it will be important that 
samples collected early after the initiation of TB treatment and regularly in the course of 
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treatment are included in such future studies, as biomarkers for early indication of the 
response to TB treatment are an urgent need worldwide.  
 
The main limitation of the current study was the small sample size. In spite of this limitation, 
we confirmed the diagnostic potentials of host markers that were only recently identified as 
potential TB diagnostic candidates, identified new TB host biosignatures, and our study was 
done on individuals that presented with signs and symptoms, prior to the establishment of a 
clinical diagnosis, and at a community level health care clinic in a high-burden setting. Further 
studies are required to validate the new findings from our study preferably in larger numbers 
of study participants presenting with signs and symptoms requiring investigation for TB 
disease, and in studies conducted in other geographical regions. As the number of HIV 
infected study participants were limited in the current study, the biosignatures identified in 
this study require further investigation in HIV infected individuals. Importantly, HIV infected 
individuals included in such future studies should be staged with CD4 cell counts and viral 
loads so as to investigate the influence of severe HIV infection on the accuracy of the 
biosignatures. As we only investigated adult culture positive TB patients in the present study, 
the utility of the biosignatures also needs to be assessed in difficult to diagnose TB cases such 
as paediatric and extrapulmonary TB, smear and culture negative TB, and also in patients 
presenting with confirmed diseases that are similar to TB, including non-TB pneumonias. 
Validated biosignatures could then be incorporated into a point-of-care screening test for TB, 
preferably based on the lateral flow technology as recently demonstrated in a multi-centered 
African study [134]. 
  
In conclusion have identified candidate host markers, some of which have not previously been 
investigated in TB, as diagnostic candidates for TB disease. The biosignatures identified in our 
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Tuberculosis (TB) remains a global health problem. According to the World Health 
Organisation (WHO), 1.5 million people died from the disease in 2014 [9]. The global TB 
epidemic continues to in part be driven by undiagnosed TB cases or delays in the diagnosis of 
the disease, which results in delays in treatment initiation and increases chances of 
transmission. Therefore the need for rapid and accurate tools for both the diagnosis and 
monitoring of TB treatment response remains a priority for the global control of the disease. 
Current diagnostic tools have several drawbacks, including the low sensitivity of the Ziehl-
Neelsen smear microscopy test and the unavailability and long turn-around time of the 
current gold standard (culture). Furthermore the long turn-around time of culture limits its 
use as a means to monitor the response to TB treatment [59,99]. The diagnosis of  TB disease 
has significantly improved with the roll-out of the automated gene amplification test 
GeneXpert (Cepheid Inc., Sunnyvale, USA), as the test greatly reduces the time to detection 
and is coupled with the identification of resistance to rifampicin. However this test is costly 
and requires infrastructure that is not readily available in resource constrained settings, and 
is therefore not ideal in these areas [62]. Immunodiagnostic approaches might be beneficial 
especially if based on more easily available sample types such as saliva, whole blood, plasma 
or serum, for both the diagnosis of TB disease and monitoring of treatment response. The 
relatively easier adaptability of host biomarker-based tests into rapid point-of-care tests, 
makes them very promising for resource-constrained settings [80]. Additionally, such tests 
may be useful particularly in circumstances where sputum collection is difficult, for example, 
in paediatric TB, and in paucibacillary forms of the disease such as extra-pulmonary TB and 
co-infection with HIV.  
 
Interferon gamma (IFN-γ) release assays (IGRAs) and the tuberculin skin test remain the most 
widely used commercially available TB immunodiagnostic tests. The use of IGRAs is however 
limited in high TB endemic areas as these assays are not useful in the diagnosis of active TB 
disease, which is a major problem in these areas with high prevalence of latent infection 
[135]. IGRAs have also generated inconsistent results as tools for monitoring of the response 
to TB treatment [95,96]. Host markers other than IFN-γ detected after overnight stimulation 
with the antigens employed in IGRAs (ESAT-6/CFP-10/TB7.7) and markers produced after 
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stimulation with novel M.tb infection phase dependent antigens have shown promise [73, 
81]. However overnight culture-based assays are unable to serve as rapid, point-of-care tests. 
Host biomarkers detected in ex vivo samples such as serum, plasma, saliva and other effusions 
have shown potential in the diagnosis of TB disease [83, 84, 136, 137]. Although saliva has 
been shown to be an important diagnostic fluid in numerous diseases, including systemic, oral 
infections, and HIV [138], not much has been done on this potentially valuable sample type 
in the TB field. Saliva is an easily obtainable sample and can be collected non-invasively with 
limited training and basic equipment. It is abundantly available in all individuals and an 
average adult has been reported to always have about 1ml of saliva in the oral cavity [139]. 
Recent studies have shown an up to 6-fold higher expression of some host biomarkers in 
saliva when compared to serum samples from TB patients [84], and that some of these host 
markers may be useful as tools for the diagnosis of TB disease and monitoring of the response 
to treatment [84,83]. Given the potential that diagnostic tools based on host biomarkers 
detected in saliva might have in the control of TB disease, it is important to continue 
investigating new host biomarkers in this potentially valuable sample type, in an attempt to 
identify better diagnostic candidates, and to refine the markers that have shown potential in 
previous studies, pending validation in larger prospective studies. In a recent large multi-
centered study conducted on serum samples [82], combinations between new and 
established host biomarkers showed potential in the diagnosis of TB disease. As most of the 
new candidate biomarkers have not been previously investigated in saliva, we aimed to 
investigate the diagnostic utility of salivary levels of these host markers for TB disease and to 
ascertain whether any of these markers were potentially useful in monitoring of the response 
to TB treatment. We also investigated the utility of biomarkers that showed potential as 
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4.2 Materials and Methods 
 
4.2.1 Study Participants 
 
As discussed in chapter 2 (section 2.1),participants included in the current study were 
recruited from the Fisantekraal Community Clinic, in the outskirts of Cape Town, South Africa, 
as part of a previously reported large study; the African European tuberculosis Consortium 
(AE-TBC; www.ae-tbc.eu). As described previously, all study participants presented with signs 
and symptoms suggestive of TB disease, including persistent cough lasting ≥2 weeks and at 
least one of either fever, malaise, recent weight loss, night sweats, knowledge of close contact 
with a TB patient, haemoptysis, chest pain or loss of appetite, and were recruited prior to 
clinical or laboratory assessment for TB disease. Participants were eligible for the study if they 
were 18 years or older and willing to give written informed consent for participation in the 
study, including consent for HIV testing. Patients were excluded if they were pregnant, had 
not been residing in the study community for more than 3 months, were severely anaemic 
(haemoglobin <10 g/l), were on anti-TB treatment, had received anti-TB treatment in the 
previous 90 days or if they were on quinolone or aminoglycoside antibiotics during the past 
60 days. Recruitment of study participants was done between November 2010 and November 
2012. The study was approved by the Health Research Ethics Committee of the Faculty of 
Medicine and Health Sciences of the University of Stellenbosch and written informed consent 
was obtained from all participants.  
4.2.2 Sample Collection and Diagnostic Tests 
 
As discussed in Chapter 2 (section 2.2.2), study participants fasted for at least one hour before 
saliva collection. Briefly, participants were asked to chew a sterile cotton swab (salivette) that 
was provided by the saliva collection kit manufacturer (Sarstedt, Numbrecht, Germany), for 
about 45 seconds. The swab was then removed from the participant’s mouth with sterile 
forceps, inserted into a sterile tube provided by the manufacturer, and then transported to 
the laboratory at 4 - 8oC. Upon arrival in the laboratory, the saliva samples were centrifuged 
at 1000g for 2 minutes and the supernatant harvested and stored at -80 oC until tested. After 
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microbiological confirmation of TB disease in study participants, sample collection was 
repeated for the culture confirmed TB patients at month 2 and month 6 after the initiation of 
TB treatment. As previously described in chapter 2 (section 2.3) and by Jacobs et al [83], 
sputum samples collected from all study participants were cultured using the MGIT method 
(BD Biosciences, Franklin Lakes, NJ, USA), after which positive MGIT cultures were examined 
for acid fast bacilli using the Ziehl-Neelsen technique (to check for contamination), followed 
by Capilia TB testing (TAUNS, Numazu, Japan), to confirm the isolation of organisms of the 
M.tb complex, before being designated as positive cultures.  
 
4.2.3 Classification of Study Participants and Reference Standard 
 
As previously described in chapter 2 (section 2.3) and by Jacobs et al [83], participants were 
classified as definite TB patients, probable TB patients, participants with other respiratory 
diseases (ORD) or questionable disease, using a combination of clinical, radiological, and 
laboratory findings. For the present discovery study however, only definite (culture positive) 
TB patients were included. Using an online tool (www.random.org), we then randomly 
selected individuals with ORD (n=33) for investigation alongside the definite TB patients with 
available saliva samples (n=18), due to the considerably higher numbers of individuals with 
ORD in our biobank. As described previously, individuals with ORD had a range of other 
diagnoses, including upper and lower respiratory tract infections (viral and bacterial 
infections, although attempts to identify organisms by bacterial or viral cultures were not 
made), and acute exacerbations of chronic obstructive pulmonary disease or asthma. Such 
investigations are not routinely done at primary health care settings, for example, where 
study participants were recruited.  
 
4.2.4 Luminex Multiplex Immunoassay 
 
The concentrations of 69 host markers, including markers that have not been widely 
investigated in the TB field (NCAM, transhyretin, MIP-4, antithrombin-III, GDF-15, ADAMTS13, 
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(in kits purchased from Merck Millipore, Billerica, MA, USA), and other host markers namely: 
alpha2 macroglobulin (A2M) , haptoglobin, C-reactive protein (CRP), serum amyloid P (SAP), 
procalcitonin (PCT), ferritin, tissue plasminogen activator (TPA), fibrinogen, serum amyloid A 
(SAA) (in kits purchased from Bio- Rad Laboratories, Hercules, CA, USA), vitronectin, 
extracellular matrix protein 1 (ECM1), vitamin D binding protein , sFas,  granzyme A, sFasL, 
sCD137, granzyme_B, perforin, myoglobulin, P-selectin, lipocalin-2, thrombopoietin (TPO), 
stem cell factor (SCF), B-cell attracting chemokine 1 (BCA-1), epithelial neutrophil activating 
protein (ENA)-78, thymic stromal lymhpopoietin (TSLP), I-309(CCL-1), stromal cell derived 
factor 1 alpha (SDF-1α), IFN-γ, IFN-α 2, interferon inducible protein (IP)-10, macrophage 
inflammatory protein (MIP)-1β, tumor necrosis factor (TNF)-α, TNF-β, vascular endothelial 
growth factor (VEGF), soluble CD40 ligand (sCD40L), apolipoprotein (Apo) A-1, Apo CIII, 
complement component 3, complement factor H (CFH), total plasminogen activator inhibitor 
1 (PAI-1), brain-derived neurotrophic factor (BDNF), cathepsin D, myeloperoxidase (MPO), 
matrix metalloproteinase (MMP)-2, MMP-9, hemofiltrate CC chemokine 1 (HCC-1), α-1-
antitrypsin, pigment epithelium derived factor (PEDF), complement C4, interleukin  (IL)-17F,  
IL-17A, IL-22, IL-33, IL-21, IL-23, IL-25, IL-31, IL-28A, IL-16, IL-1β, IL-12(p40) and IL-13 (Merck 
Millipore, Billerica, MA, USA), were investigated in saliva samples from all the study 
participants. Experiments were performed in a blinded manner, according to the instructions 
of the kit manufacturers. All assays were read on the Bio-Plex platform (Bio-Rad), with the 
Bio-Plex Software version 6.1 used for bead acquisition and analysis. 
 
4.2.5 Statistical Analysis 
 
As discussed in chapter 2 (section 2.7),differences in the concentrations of host markers 
detected in saliva samples from TB patients and individuals with ORD were evaluated using 
the Mann-Whitney U test, for non-normally distributed data, whereas the student’s t-test was 
used if data were normally distributed. The diagnostic abilities of individual host markers were 
investigated by receiver operator characteristics (ROC) curve analysis. The cut-off values for 
each analyte were determined by selecting the maximum values of Youden’s index [102]. 
General discriminant analysis (GDA) was used to determine the predictive abilities of 
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combinations of markers for the diagnosis of TB disease, with leave one-out cross validation 
[103]. Differences in the expression profiles of host markers during the course of TB treatment 
were analysed by mixed model repeated measures analysis of variance (ANOVA), with Fisher’s 
Least Significant Difference (LSD) post hoc testing. P-values ≤0.05 were considered significant. 
The data were analysed using Statistica (Statsoft, Ohio, USA) and Graphpad Prism version 5 




A total of 51 study participants, 18 of whom were culture positive TB patients were 
investigated in this study. Twelve (23.5%) of the study participants were HIV infected. The 
clinical and demographic characteristics of study participants are shown in Table 4.1. 
 
Table 4.1: Clinical and demographic characteristics of study participants. All the 18 TB 









Male, n (%) 20 (39) 4 (22) 16 (48) 
Mean age, 
(Years)±SD 
36.4 ± 9.8 39.1 ± 9.7 35 ± 9.7 
HIV infected, n (%) 12 (24) 4(22) 8 (24) 
Quantiferon results    
Positive, n (%) 30 (60) 12 (71) 18 (55) 
Negative, n (%) 19 (38) 4 (24) 15 (45) 
Indeterminate, n (%) 1 (2) 1 (6) 0 (0) 
TB= pulmonary tuberculosis, SD=standard deviation  
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4.3.1 Utility of Individual Salivary Host Markers in the Diagnosis of TB Disease 
 
Of the 69 markers investigated in the current study,  23 (vitronectin, vitamin D binding 
protein, sFas, sFasL, sCD137, perforin, ADAMTS13, P-selectin, SCF, IL-28, Apo A-1, Apo CIII, 
CFH, NCAM, BDNF, MMP-2, MIP-4, complement C4, IL-17F, IL-25 and IL-23, IL-22, IL-33) were 
barely or not detectable in saliva samples and these markers were excluded from further 
analysis. When the baseline concentrations of the remaining 46 markers in the TB patients 
(n=18) were compared to the levels obtained in the 33 individuals with ORD with the Mann 
Whitney U or student’s t test, only eight host markers were significantly different between 
the two groups. The median levels of IL-17A, IL-23 and the mean of concentrations of ECM-1 
were significantly higher in the TB patients, whereas the median levels of A2M, SAP, IL-16, IL-
1β, and the mean levels of granzyme B were significantly higher in the ORD group, whereas 
trends towards higher levels of myoglobulin and GDF-15 were observed in TB patients (Table 
4. 2). When the diagnostic accuracies of individual host markers were investigated by ROC 
curve analysis, only two markers (IL-16 and IL-23) showed promise in the present study with 
area under the ROC curve (AUC) ≥0.70, whereas A2M, SAP, IL-17A and IL-1β performed with 
AUCs ≥ 0.67 (Table 4.2). Two additional markers (GDF-15 and IL-25) became significantly 
different between the TB patients and individuals with ORD, and/or showed diagnostic 
potential (AUCs of 0.72 and 0.53 respectively) only after data for HIV infected individuals were 
excluded. Representative plots showing the levels of some of the individual host markers with 
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Table 4.2: Median levels and interquartile ranges (in parenthesis) of host markers detected 
in baseline saliva samples from the TB patients (n=18) and individuals with ORD (n=33) and 
their diagnostic accuracies for TB disease. Only markers that showed significant differences 
or trends between groups with the Mann-Whitney U test are shown. The concentrations of 
A2M, SAP, ECM1, IL-23, myoglobulin and GDF-15 are in ng/ml. The concentrations of all the 
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(59-96) 
52 (34-69) 
. aMean ± standard deviation. Data for these host markers were normally distributed  





Figure 4.1: Scatter plots showing the concentrations of host markers detected in saliva 
samples from TB patients (n=18) and individuals with ORD (n=33) and receiver operator 
characteristics curves showing the accuracies of these markers in the diagnosis of TB 
disease. Representative plots are shown for A2M, IL-16, IL-23, and IL-17A. Error bars in the 
scatter dot plots represent the median with interquartile range. 
 
4.3.2 Utility of Multi-Saliva Marker Combinations in the Diagnosis of TB 
Disease 
 
When the data obtained from all study participants were fitted into General Discriminant 
Analysis (GDA) models, regardless of HIV status, combinations between up to five different 
host markers showed potential in the diagnosis of TB disease. A three-marker biosignature 
comprising of granzyme B, fibrinogen and A2M diagnosed TB disease with a sensitivity of 
94.4% (95% CI, 74.0-99.9%) and specificity of 62.1% (95% CI, 40.6-78.5%) in the resubstitution 
classification matrix and sensitivity of 94.4% (95% CI,72.7-99.9%) and specificity of 58.6% 
(95% CI, 38.9-76.5%) after leave-one-out cross validation. However, the most optimal 
diagnostic biosignature irrespective of HIV status was a combination between five markers 
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(IL-1β, IL-23, ECM-1, HCC1 and fibrinogen) which diagnosed TB disease with a sensitivity 
88.9% (95% CI,76.7-99.9%) and specificity of 89.7% (95% CI, 60.4-96.6%) in the resubstitution 
classification matrix, and with the same  accuracy (sensitivity of 88.9% and specificity of 
89.7%) after leave-one-out cross validation. The positive and negative predictive values of the 
five-marker biosignature were 89.7% (95% CI, 76.7-97.8%) and 88.9% (95% CI, 65.3-98.6%) 
respectively. 
 
When the GDA procedure was repeated after excluding the HIV infected individuals, two 
eight-marker biosignatures diagnosed TB disease with high accuracies. A biosignature 
comprising of granzyme A, GDF-15, SAA, IL-21, ENA-78, IL-12(p40), IL-13 and PAI-1,diagnosed 
TB disease with sensitivity of 93% (95% CI, 77.2-99.9% ) and specificity of 100% (95% CI, 75.3-
100% ) in the resubstitution classification matrix, and after leave-one-out cross validation, 
whereas a biosignature comprising of ECM1, myoglobulin, HCC1, IL-21, ENA-78, TPA, IL-
12(p40) and IL-13 diagnosed TB disease with sensitivity of 100% (95% CI, 83.2-100%) and 
specificity of 95% (95% CI, 68.1-99.9% ) in the resubstitution classification matrix, and after 
leave-one-out cross validation. IL-1β was the most frequent analyte in biosignatures, 
appearing in 93% of the biosignatures generated for diagnosing TB disease regardless of HIV 
infection status (Figure 4.2).  





Figure 4.2: Accuracy of salivary multi-marker models in the diagnosis of TB disease. Receiver 
operator characteristics (ROC) curve showing the accuracy of the optimal five-marker 
biosignature (IL-1β, IL-23, ECM1, HCC1, fibrinogen) in the diagnosis of TB disease in all study 
participants, regardless of HIV infection status (A), frequency of analytes in top general 
discriminant analysis (GDA) models that most accurately classified individuals as TB patients 
or ORD irrespective of HIV status (B), ROC curve showing the accuracy of the most accurate 
eight-marker biosignature (granzyme A+PAI-1+GDF-15+SAA+IL-21+ENA-78+IL-12(p40) and IL-
13)  in the diagnosis of TB disease after exclusion of HIV positive individuals  (C), and frequency 
of analytes in the top GDA models that most accurately classified study participants as TB or 
ORD in the absence of HIV infection (D). The bar graphs (B and D) indicate the frequency of 
analytes in the most accurate GDA models.  
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4.3.3 Changes in the Concentrations of Host Biomarkers during the Course of 
TB Treatment 
 
To investigate whether any of the 46 detectable host markers could potentially be used as 
markers to monitor TB treatment response, we evaluated the concentrations of the markers 
in saliva samples that were collected from TB patients at baseline, and at months 2 and 6, 
following the start of TB treatment. Of the 18 TB patients included in the study, all 18 (100%) 
and 13 (72%) returned to the clinic and provided samples at months 2 and 6 respectively, and 
these samples were used in this part of the study. The salivary concentrations of 8 host 
markers changed significantly during the course of treatment. There was a significant 
decrease in the levels of haptoglobin and CRP from baseline to month 2, but a significant 
increase in ENA-78 levels over the same period (Figure 4. 3, Table 4.3). The levels of ENA-78 
continued to increase towards month 6. The levels of IP-10, MIP-1β and VEGF increased 
significantly when baseline levels were compared to end of treatment (month 6) levels, 
whereas the levels of lipocalin-2 significantly decreased and a trend towards decreasing levels 
of ECM1 from baseline to month 6 was observed (Figure 4.3, Table 4.3). There were no 
significant differences in transthyretin levels between diagnosis and month 2, but the increase 
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Table 4.3: Mean values of host makers detected in saliva samples of TB patients at baseline, 
month 2 and month 6 (after the start of TB treatment). Data were analysed using mixed 
model repeated measures analysis of variance, with Fisher’s Least Significant Difference post 
hoc testing. The mean values shown (95% confidence intervals in brackets) are the least 
squared means. Significant P-values are in bold. 
 
Time point P value 










































IL-17A 13.4 (9-17.9) 8.2 (4.7-11.7) 9 (3.6-14.3) 0.064 0.74 0.16 




0.083 0.83 0.17 
       



































17.6 (10-25.3) 23.7 (11.3-36) 0.38 0.098 0.022 


























447 (359-535) 0.18 0.30 0.034 




Figure 4.3: Changes in the concentrations of host markers in saliva samples from TB patients 
undergoing TB treatment. Saliva samples were collected from all study participants at 
baseline (before the start of treatment) and at months 2 and 6 after initiation of TB treatment. 
Error bars indicate the Least Squared means with 95% Confidence Intervals. 
 
4.3.4 Comparison of the Levels of Host Markers Detected in Saliva to the 
Levels Obtained in Plasma 
 
As the study participants whose samples were evaluated in this chapter were also evaluated 
in chapter 3, we compared the levels of all the 69 host markers evaluated in saliva samples in 
this chapter to the levels obtained in plasma samples from the same study participants in 
chapter 3. This was necessary given that 23 of the 69 host markers evaluated were barely 
detectable in saliva samples as mentioned earlier in this chapter. Data on differential 
expression of the host markers in the two sample types may be beneficial when designing 
future experiments. Using data obtained from the manufacturer’s package inserts, we 
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evaluated the proportion of patients in whom the concentrations of the different host 
markers in saliva and plasma were ≥ the published minimum detectable concentration (MDC). 
P-values for differential expression of the markers in saliva and plasma samples were 
computed using the Mann Whitney U test. 
  
Out of the 69 markers evaluated, information about the MDC was not available for 9 (kits 
purchased from Bio Rad laboratories) namely; A2M, haptoglobin, CRP, SAP, PCT, ferritin, TPA, 
fibrinogen and SAA. The concentrations of three of the proteins (lipocalin-2, Cathepsin D and 
TNF-α) were higher than the MDC +2 standard deviations in both sample types, in all study 
participants whereas values for none of the  proteins in saliva and 14 proteins in plasma were 
above the MDC in all samples respectively (see table 4.4). 
 
The mean and/or median concentrations of eight of the proteins (lipocalin-2, TSLP, IL-16, IL-
1β, IFN-α2, IL-13, VEGF and IL-17A) were significantly higher in saliva samples when compared 
to plasma, and the levels of seven (granzyme A, granzyme B, IL-28, IFN-γ, TNF-β, MPO and IL-
21) showed no difference in expression levels between saliva and plasma, whereas all the 
remaining markers were significantly higher in plasma than in saliva (Table 4.4).  
 
Table 4.4: Proportion of study participants with host markers above the minimum 
detectable concentration in saliva and plasma and differences in median levels detected in 
the two sample types. The MDC values shown include 2x standard deviations (MDC +2SD) 
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#SAA NA NA 0.0 ( 0.0- 35.29) NA 8347 <0.0001 
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#ECM-1 0.003  
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*SCF 5.6  
 
0.0 0.34 (±1.09) 10.6 4.17 (±14.64) 0.0061 
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#*IL-17F 0.016  0.0 0.0 31.9 0.014 - 
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 (±0.0) (±0.023) 




































No differences in the levels expressed in saliva and plasma 
 


















17.0 20.07 (±67.69) 0.25 





*TNF-β 1.9 23.4 1.74 23.4 10.45 0.53 









*Mean ± standard deviation are shown for host markers whose values were normally 
distributed. # Marker levels are expressed in ng/ml. All other analyte levels are in pg/ml. 
4.4 Discussion 
 
In the present study, we evaluated the potential usefulness of 69 host markers as candidates 
for the salivary immunological diagnosis of TB disease and monitoring of the response to TB 
treatment. Although significant differences were observed in the concentrations of some of 
the markers including A2M, SAP, IL-17A, IL-1β, ECM1, IL-16, IL-23 and granzyme B , our study 
confirmed the notion that optimal diagnosis of TB disease may only be possible using 
biosignatures containing multiple analytes, as opposed to single markers. The most optimal 
biosignature identified in the present study was a five-marker signature comprising of IL-1β, 
IL-23, ECM-1, HCC1 and fibrinogen, which diagnosed TB disease with a sensitivity of 88.9% 
and specificity of 89.7%, regardless of HIV infection status. After excluding the HIV positive 
individuals, eight-marker biosignatures diagnosed TB disease with both sensitivity and 
specificity up to 100%, depending on the markers in the biosignature. 
    
TB immunological tests may be more beneficial especially in resource-constrained settings, 
as they may be easily converted into point-of-care screening tests. Such tests would yield the 
highest impact if based on host markers that are detectable in easily available samples such 
as saliva, and are preferably based on the lateral flow technology. Out of the 69 host markers 
investigated in the current study, fibrinogen, antithrombin III, A2M, SAA, SAP, IL-1β, IL-23, IL-
21, IL-13, IL-12(p40), HCC1, ENA-78, GDF-15, myoglobulin, TPA, granzyme A, granzyme B,  PAI-
1, α-1-antitrypsin, and complement C3, featured in diagnostic biosignatures for TB disease, 
(±4.16) (±32.61) 
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thereby indicating that they may be candidate  biomarkers for inclusion into future salivary 
diagnostic validation studies. Although most of these proteins are well-known and have been 
investigated widely in other diseases including TB [120, 140–142], most of them have not 
previously been investigated in saliva samples, especially in the context of active TB disease. 
  
In a previous small study comparing the expression of host markers in saliva to serum, vast 
differences were observed in the expression of host markers in saliva and serum, with some 
salivary host markers showing potential as diagnostic candidates [84]. In a relatively larger 
follow-up study [83], some of the potential host markers identified in [84] continued to show 
promise, with new host markers, and also markers showing potential as TB treatment 
response candidates identified [83]. IL-1β and IL-13 were amongst the markers that were 
more abundantly expressed in saliva, and IL-1β was included in top salivary biosignatures for 
the diagnosis of TB disease [84], as also observed in the current study. In addition to these 
two cytokines, other markers that showed potential in the present study as determined by p-
values for differences between TB and ORD or inclusion into top biosignatures, and which 
were also identified in the two previous saliva based studies [84,83] as diagnostic candidates 
including fibrinogen, A2M, CRP, IP-10, MIP-1β, IL-17, VEGF and SAP, may be strong candidates 
for further investigation in future larger studies. Despite the agreement observed between 
the current and the two previous saliva based studies [84,83], we observed some differences 
between the current, and these previous studies. Although A2M and SAP were identified as 
important diagnostic candidates in this and the previous studies [84,83], we observed higher 
levels of A2M and SAP in saliva samples from individuals with ORD in the present study, in 
comparison to higher levels of these markers in TB patients in one of the relatively larger 
previous studies [83]. Although it may not be possible to completely explain the reasons for 
these differences, the use of limited numbers of study participants and the real potential for 
false discoveries exist, as patients used in these studies were not homogenous. The study by 
Phalane et al [84] as a small case-control study which was primarily aimed at investigating 
whether there were any differences in the expression of host markers between saliva and 
serum samples. The previous study by Jacobs et al [83] was a relatively larger study that was 
conducted on individuals that presented with signs and symptoms of TB, who were 
consecutively recruited, much like the study participants included in the current study. 
However only culture positive TB patients (n=18), four of whom were HIV infected and 
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randomly selected individuals with ORD were included in the current study, due to high costs 
associated with investigating the relatively large numbers of  host markers in this study. 
Although the findings from all these studies require careful interpretation because of the 
heterogeneity in the studies, the potential host markers so far identified through these 
studies may be regarded as candidate biomarkers, requiring validation in larger studies. We 
also identified new salivary diagnostic candidate markers in the current study including IL-16, 
IL-23 and ECM-1.  
 
IL-16 is a pro-inflammatory cytokine and a ligand for CD4+ T lymphocytes [143] and in the 
context of HIV, has been shown to inhibit the replication of the virus, with serum levels 
decreasing with HIV disease progression [144]. IL-23 is important in the Th17 pathway in M.tb 
infection, and is generally produced by alveolar macrophages and dendritic cells [144]. ECM-
1 is a glycoprotein and plays a role in angiogenesis, and has been implicated in tumor 
progression [145,146]. IL-23 was amongst the markers included in the optimal five-marker 
signature identified in the present study and also showed promise individually as a diagnostic 
candidate for TB disease.  Although not expressed at high levels, the concentrations of IL-23 
and ECM1 were significantly higher in TB patients, with IL-16 levels higher in patients with 
ORD in the current study. These markers warrant inclusion into analyte panels in future 
validation studies.   
  
We also investigated salivary levels of newly identified serum and plasma diagnostic host 
markers including NCAM, MIP-4 [147], transthyretin, Apo A-1 amongst others [82]. The levels 
of Apo A-1, NCAM and MIP-4 were not detectable in saliva samples in the current study, 
whereas transthyretin levels were not significantly different between TB patients and 
individuals with ORD, even though transthyretin showed potential as a marker of TB 
treatment response. Although salivary GDF-15 levels showed a trend towards higher levels in 
TB patients, the data obtained in the current study indicates that most of these markers may 
not be useful as diagnostic candidates in saliva, and require further investigation. 
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In addition to being potential salivary TB diagnostic candidates, Il-17A, IL-23 and ECM-1 also 
showed potential as markers for TB treatment response. The high concentrations observed 
for these markers in TB patients in comparison to ORD at baseline, reduced (although not 
always significantly) in the course of TB treatment. Our observations for CRP, IP-10 and VEGF 
as salivary candidate markers for monitoring of the response to treatment  are in agreement 
with previous investigations [83,132,148]. As discussed previously [83], larger studies are 
required to validate the potential of these markers as biomarkers for TB treatment response. 
Such studies should include samples collected at earlier time points, for investigation of 
markers of early TB treatment response, and should also investigate whether these markers 
are informative in the prediction of month 2 culture outcome, favourable treatment outcome 
(clinical cure) and poor outcomes (relapse and treatment failure). 
  
When comparing the levels of 69 markers in saliva samples to the levels obtained in plasma 
for the same study participants, differences in the expression of host markers were found 
between the two sample types. Eight markers (Lipocalin-2, TSLP, IL-16, IL-1β, IFN-α2, IL-13, 
VEGF and IL-17A) were found to be significantly higher in saliva samples. Our findings are in 
agreement to a previous study conducted in our laboratory which also showed significantly 
higher levels of expression for IL-1β, IL-13, VEGF and IL-17A in saliva [84]. Both IL-13 and IL-
1β were included in biosignatures generated in the present study and therefore further 
supports the idea of saliva being a valuable sample type for research in TB biomarker 
discovery. 
 
The main limitation of our study was the small sample size. As this was largely a discovery 
study, this might not be a major problem especially as we also confirmed findings from 
previous studies [84,83]. The few discrepancies between the markers identified in this and 
previous studies [84,83], strengthen the argument for the need for further validation of these 
candidate markers in larger studies before they may be considered for incorporated into 
point-of-care lateral flow test platforms. Although incorporation of host markers identified in 
the laboratory using platforms such as the Luminex technology into point-of-care tests is 
challenging, recent advances in technology have made such tasks possible. A prototype of 
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such a point-of-care test was recently developed and successfully investigated in a recent Pan-
African study [80], with further development of the platform ongoing (www.screen-tb.eu). 
The strength of such a test, based on validated biomarkers including the ones identified in the 
present study include non-invasive sampling, and such a test might be very useful in the 
diagnosis of paucibacillary TB.  The effect of HIV infection and other comorbidities such as 
diabetes mellitus on salivary biomarkers requires investigated in future studies. Furthermore, 
such studies should also include individuals with confirmed other diseases that present with 
symptoms that are similar to TB including pneumonia. 
  
In conclusion, we have identified candidate salivary biosignatures with potential in the 
diagnosis of TB disease and monitoring of TB treatment response. Our findings require further 






















Utility of antibodies against recently identified 
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Tuberculosis (TB) remains one of the leading death causing infectious diseases worldwide, 
being responsible for nearly 1.5 million deaths in 2014 [9]. The control of the disease largely 
depends on early case detection and proper treatment, therefore in order to reduce the 
burden of the disease, rapid and accurate tools for both the diagnosis and monitoring of TB 
treatment response are required. Existing methods for the diagnosis of TB disease still largely 
rely on initial clinical suspicion and subsequent microbiological confirmation by Ziehl-Neelsen 
staining and culture. However these methods have several drawbacks: -smear microscopy is 
the most common and affordable method used especially in resource poor settings, however 
it’s sensitivity is compromised and in addition this approach is also unable to distinguish 
between live and dead bacilli, making it impractical to be used as a tool to monitor TB 
treatment response [59, 99]. Although the gold standard test for TB (culture) is more 
sensitive, this method requires bacterial growth of up to 6-8 weeks before case detection and 
is consequently also not suitable for monitoring TB treatment response. The automated gene 
amplification test GeneXpert (Cepheid Inc., Sunnyvale, USA) is more rapid and is also able to 
detect resistance to rifampicin [63]. However the use of the test is limited in resource 
constrained settings due to high operating costs and infrastructural needs. Immunodiagnostic 
assays may be useful for both the diagnosis of TB disease and monitoring of the response to 
treatment especially since they have the potential to be easily adaptable into rapid, point-of-
care tests, which would be suitable at primary health care centres in resource-constrained 
settings.  
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Previous studies have shown that exposure to M.tb elicits antibody production to various 
antigens [149, 150]. TB serological diagnostic assays have been widely investigated, and have 
been improved over the years by using highly purified recombinant antigens, as previous 
generations of the assays were criticized for their low sensitivity in TB endemic regions 
[151,79]. As demonstrated in previous chapters of this thesis and in several previous studies, 
inflammatory biomarkers may be very useful in the diagnosis of TB disease [82, 98, 100]. As 
these inflammatory biomarkers are known to not be very disease-specific, consequently 
having sub-optimal specificity for TB, it is not known whether combining the cytokine 
biomarkers (traditionally good sensitivity but poor specificity) with antibodies which are 
traditionally very specific (but with poor sensitivity) will result in a better diagnostic 
biosignature for TB disease. A biosignature making use of both classes of biomarkers may 
therefore benefit from the strengths of each individual diagnostic approach.  
  
Previous studies conducted in our laboratory evaluated antibodies against novel M.tb 
antigens for their ability to diagnose TB disease and as tools for monitoring of the response 
to TB treatment. These studies revealed that a combination of multiple antibody classes (Ig 
A, Ig G, Ig M) against multiple M.tb antigens including LAM, Tpx and PPE proteins ascertained 
TB disease with high accuracy [78]. Furthermore, combinations between other antibodies  
including anti-alanine dehydrogenase IgG, anti-Tpx IgG, anti-ESAT-6 IgG and anti-ESAT-6 IgA, 
measured prior to TB treatment initiation showed promise as markers for the prediction of 
early TB treatment response [152]. However, in other work done by Legesse et al, it was 
demonstrated that the discriminatory ability of M.tb-specific IgA antibodies is better than IgG 
antibodies between active TB and endemic controls in Africa [153]. This was also the case 
between healthy individuals with close contact to a TB patient and individuals with no contact 
with such patients in another study [154], with other studies also demonstrating a protective 
role for IgA in murine models of mycobacterial infection [155]. Contrary to previous work that 
was conducted in our laboratory, the present study focused on IgA antibodies. Furthermore, 
we explored the utility of IgM antibodies against LAM as this kit was not available in previous 
panels evaluated in our high endemic TB setting. 
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The aim of the present study was therefore to explore the diagnostic potential of Ig A 
antibodies against six M.tb specific antigens, and IgM antibodies against LAM in plasma 
samples from active TB cases and individuals with other respiratory diseases (ORD). To 
investigate whether the diagnostic accuracy for TB disease would improve if anti-M.tb 
antibodies were used in combination with cytokine biomarkers, we evaluated a diagnostic 
approach in which the two classes of biomarkers were combined. Furthermore, we also 
evaluated the potential of the antibodies as markers for monitoring of TB treatment response. 
 
5.2 Materials and Methods 
 
5.2.1 Study Participants 
 
As discussed in chapter 2 (section 2.1) , participants enrolled into the present study were 
individuals who presented with signs and symptoms requiring investigation for TB disease at 
the Fisantekraal Community Clinic in the outskirts of Cape Town, South Africa. The study was 
a sub-study of a larger diagnostic biomarker project (the African European Tuberculosis 
Consortium), that was ongoing at the study site and at field sites situated in six other African 
countries (www.ae-tbc.eu). 
  
5.2.2 Samples and Laboratory Experiments 
 
Plasma samples were collected and processed as described in chapter 2 (section 2.2.1). ELISA 
experiments were performed on all study participants as described in chapter 2 (section 2.6), 
following the optimization experiments reported in section 2.8.3.Data were analysed using 
Statistica (Statsoft, Ohio, USA) and Graphpad Prism version 5 (Graphpad Software Inc., CA, 
USA) as described in chapter 2 (section 2.7) . Briefly, differences in the antibody responses 
between TB patients and individuals with ORD were analysed using the Mann-Whitney U test. 
The diagnostic abilities of individual antibody responses were assessed by receiver operator 
characteristics (ROC) curve analysis. The cut-off values for each antibody and associated 
sensitivity and specificity were determined by selecting the maximum values of Youden’s 
index [102]. The predictive abilities of combinations of between different antibodies and 
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between antibodies, cytokines and other parameters were investigated by general 
discriminant analysis (GDA), with leave-one-out cross validation [103]. Differences in the 
levels of antibodies during the course of TB treatment were analysed using mixed model 
repeated measures analysis of variance (ANOVA), with Fisher’s Least Significant Difference 




A total of 156 study participants, 22 of whom were definite and 4 that were probable TB 
patients (please see table 2.1) were investigated in this study. The mean age of all study 
participants was 37 ± 11.2 years and 28 (18%) were HIV infected. The clinical and demographic 
characteristics of study participants enrolled for this chapter are shown in table 5. 1. 
Table 5. 1: Clinical and demographic characteristics of study participants. 














Males, n (%) 65 (42) 6 (27) 0 (0) 6 (23) 59 (45) 
Mean age, 
(Years)±SD 
37 ± 11.2 39 ±9.9 40 ± 11.4 39 ± 9.9 37 ±11.5 
HIV Infected, n (%)  28 (18) 4 (18) 0 (0) 4 (15) 24 (18) 
Quantiferon results      
Positive, n (%) 104 (70) 16 (80) 3 (75) 19 (79) 85 (69) 
Negative, n (%) 43 (29) 3 (15) 1 (25) 4 (17) 39 (31) 
Indeterminate, n (%) 1 (1) 1 (5) 0 (0) 1 (4) 0 (0) 
Symptoms at enrolment 
Cough, n (%) 156 (100) 22 (100) 4 (100) 26 (100) 130 (100) 
Weight loss, n (%) 103 (66) 16 (23) 4 (100) 20 (77) 83 (64) 
Sputum production, n 
(%) 
155 (99) 22 (100) 4 (100) 26 (100) 129 (99) 
Night sweats, n (%) 110 (71) 19 (86) 4 (100) 23 (88) 87 (67) 
Malaise, n (%) 87 (56) 15 (68) 3 (75) 18 (69) 69 (53) 
Fever, n (%) 44 (28) 10 (45) 2 (50) 12 (46) 32 (25) 
Anorexia, n (%) 80 (51) 13 (59) 4 (100) 17 (65) 63 (48) 
Haemoptysis, n (%) 23 (15) 4 (18) 1 (25) 5 (19) 18 (14) 
Chest pain, n (%)  115 (74) 19 (86) 3 (75) 22 (85) 93 (72) 
Short Breath, n (%) 129 (83) 18 (82) 3 (75) 21 (81) 108 (83) 
Abbreviations: TB= pulmonary tuberculosis, SD=standard deviation  
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5.3.1 Utility of Individual anti-M.tb Antibodies in the Diagnosis of TB Disease  
 
Titres of IgA antibodies against six antigens (Apa, “Kit 1”, “Kit 2”, NarL, Rv3019c and PstS1) 
and titres of IgM antibodies against LAM (Table 2.3) were measured in a blinded manner, 
according to the instructions of the kit manufacturer, in plasma samples from 156 study 
participants. When the baseline levels of the antibodies detected in the TB patients (n=26) 
were compared to the levels obtained in the 130 individuals with ORD with the Mann-
Whitney U test, IgA antibodies against four M.tb antigens (Rv3019c, “Kit 1”,”Kit 2” and NarL) 
differentiated significantly between active TB patients and individuals with ORD (Table 5.2, 
Figure 5.1). When the diagnostic accuracies of individual antibodies were investigated by ROC 
curve analysis, anti-NarL IgA was the only individual antibody that showed promise, with an 
area under curve (AUC) of 0.74 (95% CI, 0.64-0.83) and sensitivity and specificity of 92% (95% 
CI, 75-99%) and 52% (95% CI, 34-60%) respectively. anti-Rv3019c IgA and anti-“Kit 2” IgA 
performed with AUCs ≥ 0.66 (Table 5.2, Figure 5.1). When data was stratified according to HIV 
infection status the levels of anti-Psts1 IgA became significant between the two groups with 
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Table 5.2: Median optical density (OD 450) values (and inter-quartile ranges in parenthesis) and diagnostic accuracies of individual antibodies 
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Figure 5.1: Scatter plots showing the median optical density (450nm) for anti-Rv3019c IgA, 
anti-“Kit 1” IgA, anti-“Kit 2” IgA and anti-NarL IgA in plasma samples from TB patients (n=26) 
and individuals with ORD (n=130) and receiver operator characteristics curves showing the 
accuracies of these antigens in the diagnosis of TB disease. Error bars in the scatter dot plots 
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5.3.2 Utility of Multi-Antibody Models in the Diagnosis of TB Disease 
 
When data obtained from all study participants were fitted into General Discriminant Analysis 
(GDA) models, regardless of HIV status, all seven antibodies investigated (anti-Rv3019c 
IgA+anti-PstS1 IgA+ anti-“Kit 1” IgA+ anti-“Kit 2” IgA+ anti-Apa IgA+ anti-NarL IgA+ anti-LAM 
IgM), when used in combination, discriminated between TB patients and individuals with ORD 
with AUC of 0.8 (95% CI, 0.72-0.88) (Figure 5.2).This resulted to a sensitivity of 65.4% (95% CI 
44.4-82%) and specificity of 76.9% (95% CI, 68.6-83.7%) in the resubstitution classification 
matrix, and a sensitivity of 58% (95% CI, 37.2-76%) and specificity of 78% (95% CI, 66.9-82.3%) 
after leave-one- out cross validation. The positive and negative predictive values of the seven-
marker antibody signature were 58% (95% CI, 37.2-76.0 %) and 75.3% (95% CI, 66.9-82.3 %) 
respectively after leave-one-out cross validation.  
 
When the GDA procedure was repeated after excluding the HIV infected individuals the 
seven-marker antibody combination diagnosed TB disease with an AUC of 0.79 (95% CI, 0.7-
0.89) (Figure 5.2)., corresponding to a sensitivity of 55% (95% CI, 32.7-74.9%) and specificity 
of 80.2% (95% CI,71.1-87.1%) in the resubstitution classification matrix, and sensitivity of 50% 
(95% CI, 37.2-76%) and specificity of 76%(95% CI, 66.9-82.3%)  after leave one out cross 
validation (Figure 5.2).  
 




Figure 5.2: Accuracy of multi-marker models in the serodiagnosis of TB disease. Receiver 
operating curve characteristics (ROC) curve showing the accuracy of a seven-marker 
biosignature (anti-Apa IgA, anti- “Kit 1” IgA, anti-“Kit 2” IgA, anti- NarL IgA, anti-Rv3019c IgA, 
anti- PstS1 IgA and anti-LAM IgM) in all study participants, regardless of HIV infection (A), ROC 
curve showing the diagnostic accuracy of the seven-marker biosignature (anti-Apa IgA, anti- 
“Kit 1” IgA, anti-“Kit 2” IgA, anti- NarL IgA, anti-Rv3019c IgA, anti- PstS1 IgA and anti-LAM IgM)  
in HIV negative individuals (B). 
 
5.3.3 Diagnostic Accuracy of Multi-Antibody Models when used in 
Combination with Cytokines 
 
During the design of the present study, attempts were made at ensuring that there are 
common study participants between the study reported in Chapter 3 and the present study. 
This study design provided the opportunity for us to investigate the utility of combinations 
between inflammatory host markers (investigated in chapter 3) and the antibody responses 
investigated in the current chapter. A total of 46 study participants (20 culture confirmed TB 
patients and 26 individuals with ORD individuals) were common between chapter 3 and the 
present chapter. When the host inflammatory biomarker- and the antibody data obtained 
from these participants were fitted into GDA models, regardless of HIV status, a biosignature 
comprising of a combination between anti-“Kit 1” IgA and 5 host markers namely; neural cell 
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adhesion molecule (NCAM), vitronectin, complement factor H, ferritin and α-2 macroglobulin 
(A2M) diagnosed TB disease with a sensitivity of 95% (95% CI, 73-100%) and specificity of 
88.5% (95% CI, 68.7-97%), both in the resubstitution classification matrix and after leave-one-
out cross validation (Figure 5.3). The positive and negative predictive values of this 
biosignature was 86.4% (95% CI, 64-96.4%) and 95.8% (95% CI, 76.9-99.8%) respectively.  
 
Figure 5.3: Accuracy of multi-marker models for host markers and antibody combinations 
for the diagnosis of TB disease. Receiver operating curve characteristics (ROC) curve 
showing diagnostic accuracy of the six-marker biosignature (anti-“Kit 1” IgA, NCAM, 
vitronectin, Complement factor H, ferritin and A2M in all participants, regardless of HIV 
infection (A), frequency of analytes in the top 7 general discriminant analysis (GDA) models 
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5.3.4 Diagnostic Accuracy of Multi-Antibody Models when used in 
Combination with Symptoms 
 
To investigate whether the use of antibody responses had the potential to contribute to the 
diagnosis of TB disease when used in combination with symptoms, antibody titres together 
with the symptoms (see table 5.1) that participants presented with at enrolment were fitted 
into GDA models. When night sweats and shortness of breath were combined with anti-“Kit 
1” IgA, anti-“Kit 2” IgA, anti-Apa IgA and anti-NarL IgA responses, this antibody-symptom 
combination diagnosed TB disease with a sensitivity of 85% (95% CI, 64.3-95% ) and specificity 
of 72% (95% CI, 62.8-78.9%) in the resubstitution classification matrix, and sensitivity and 
specificity of 85% (95%CI, 64.3-95% ) and 71% (95% CI, 62-78.2% ) after leave-one-out cross 
validation respectively. The positive and negative predictive values of this biosignature were 
84. % (95% CI, 64.2-94.9%) and 70.8% (95% CI, 62.0-78.2%) respectively after leave-one out- 
cross validation (Figure 5.4). When the GDA procedure was repeated after excluding the HIV 
infected individuals  the most optimal biosignature was a combination between anti-Apa IgA, 
NarL IgA, night sweats, malaise and shortness of breath, which discriminated between the TB 
disease and ORD group with an AUC of 0.81 (95% CI, 0.7-0.92) (Figure 5.4), corresponding to 
a sensitivity of 86.4% (95% CI, 64-96.4% ) and specificity of 74.5%  (95% CI, 65-96.4%) in the 
resubstitution classification matrix, and sensitivity and specificity of 82% (95% CI, 59-94%) and 
73% (95% CI, 63-80.1%) respectively after leave-one-out cross validation. Anti-Apa IgA was 
the most frequent antibody and night sweats the most frequent symptom in GDA 
biosignatures, appearing in 54% and 46% of the biosignatures generated for diagnosing TB 
regardless of HIV infection status respectively (Figure 5.4).  




Figure 5.4: Accuracy of multi-marker models for antibody and symptoms combinations in 
the diagnosis of TB disease. Receiver operating curve characteristics (ROC) curve showing 
diagnostic accuracy of  the six-marker biosignature (anti-“Kit 1” IgA, anti-“Kit 2” IgA, anti-
Apa IgA, anti-NarL IgA, night sweats and short breath) in all participants, regardless of HIV 
infection (A), frequency of anlaytes in the top 28 general discriminant analysis (GDA) models 
that most accurately classified study participants as TB disease or ORD irrespective of HIV 
status (B),ROC curve showing the diagnostic accuracy of a five marker biosignature (anti-Apa 
IgA,anti- NarL IgA, night sweats, malaise and short breath) in HIV negative individuals (C). 
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5.3.5 Changes in Antibody Levels during the Course of TB Treatment 
 
To investigate whether the levels of the antibodies investigated in the present study could 
potentially be used to monitor TB treatment response, we evaluated the antibody levels 
against five of the M.tb antigens (Rv3019c, PstS1, Apa, NarL and LAM) in plasma samples that 
were collected from TB patients at baseline, months 2 and 6, following the start of TB 
treatment. Samples collected at month 2 following the initiation of TB treatment were 
available from 25(96%) of the 26 TB patients, and from 21 (81%) of the patients after 
treatment completion (month 6).  None of the antibodies showed significant changes in the 
course of treatment, when the OD values read at 450nm were considered. When a reference 
filter (650nm) was employed with the 450nm measurements, the significant changes were 
observed in the titres of four of the antibodies (Figure 5.5). The titres of anti- Rv3019c IgA 
increase significantly from baseline to month 2, whereas a decrease was observed towards 
the end of treatment. Anti-Psts1 IgA and anti-Apa IgA levels significantly decreased from 
month 2 to month 6, whereas anti-NarL IgA levels significantly decreased throughout the 









Figure 5.5: Baseline, month 2 and month 6 (after treatment) mean optical density (450nm-
650nm) values of antibodies in plasma samples from TB patients. Error bars indicate the 
Least Squared means with 95% Confidence Intervals 
 





















































































































Serological diagnostic methods for TB disease have extensively been studied with variable 
success [79]. Although the World Health Organisation (WHO) advised against the use of 
commercial serological tests for the diagnosis of TB due their suboptimal performance in the 
negative policy document [70] it encouraged further investigations on strategies to improve 
the accuracies of these tests. Previous studies demonstrated a role for antibodies during 
protection against intracellular pathogens via various mechanisms [156, 157]. Antibodies 
could possibly mediate protection by preventing pathogens from entering cells or by 
enhancing the production of pro-inflammatory cytokines [158, 159]. In the case of TB de 
Valiere et al demonstrated that antibodies enhances cellular immune responses in order to 
protect the host [160]. In the present study, we evaluated the serodiagnostic potentials of 
antibodies against seven M.tb specific antigens (Apa, “Kit 1”, “Kit 2”, NarL, Rv3019c, PstS1 and 
LAM) for the immunological diagnosis of TB disease and monitoring of TB treatment response. 
IgA antibody responses against NarL, Rv3019c, “Kit 1”and“Kit 2” were significantly different 
between TB patients and individuals with ORD, with the most promising single antibody being 
anti-NarL IgA.  We also demonstrated that the diagnostic performance of antibodies can be 
improved by using a combination of antigens as well as by combining antibody measurements 
with cytokine inflammatory biomarker measurements and clinical symptoms.  
 
NarL has been described as a putative nitrate response regulator and is part of the membrane 
fraction of M.tb [161, 162]. IgA antibody responses against NarL in serum samples have 
previously been investigated for the diagnosis of active TB disease, and discriminated 
between active TB patients and healthy controls with 78.6% sensitivity and 100% specificity 
[163]. Our findings that IgA antibodies against NarL may be useful in the diagnosis of TB 
disease are therefore in keeping with these previous observations. When the TB-specific 
antibodies were used in combination with initial clinical symptoms that patients presented 
with at enrolment, the most optimal biosignature was a combination between anti-“Kit 1” 
IgA, anti-“Kit 2” IgA, anti-Apa IgA, anti-NarL IgA, night sweats and shortness of breath, which 
diagnosed TB disease with sensitivity and specificity of 85% and 72% respectively and the 
same AUC (0.80), was obtained as when multiple antibodies were used in combination.  




Apa is an actively secreted antigen of M.tb and IgA responses against this antigen have 
previously been investigated. Apa diagnosed TB disease in serum samples with promising 
accuracy [78]. Furthermore, the antigen has been shown to be useful in the diagnosis of TB 
at the early stages of disease, and may also be useful in individuals co-infected with HIV [164]. 
Although Apa alone did not perform well in the current study, it was the most frequently 
appearing antigen in the multi-antigen biosignatures that were generated. This antigen was 
also included in an antigenic cocktail (Apa, CFP-10, ESAT-6, PstS-1 and Ag85) that was 
generated in a Cuban population for the diagnosis of active TB disease, and diagnosed TB with 
a sensitivity of 87.1% and specificity of 97.1% [165], thereby indicating the potential of this 
antigen in combination with other M.tb specific antigens  as useful diagnostic tool for active 
TB. 
 
With the aim of further improving the sensitivity and specificity for the diagnosis of TB 
disease, we also investigated an approach in which inflammatory host biomarker responses 
were combined with antibodies against these TB-specific antibodies. Several studies have 
demonstrated the potential usefulness of cytokines in the diagnosis of TB disease [82, 98, 
100]. However, it is well-established that these markers are not particularly disease specific, 
as their levels are raised in multiple infections and non-infectious inflammatory conditions. A 
biosignature comprising of a combination between anti-“Kit 1” IgA and five cytokines (NCAM, 
vitronectin, Complement factor H, ferritin and A2M) diagnosed TB disease in the present 
study, with a sensitivity of 95% and specificity of 88.5%, and with a negative predictive value 
of 95.8%. NCAM has been found to be important in cell-cell or cell-matrix interactions [129] 
and its role in lung tumor progression has been described [130]. The potential of NCAM as a 
diagnostic marker for TB disease has recently been identified in a study conducted in our 
laboratory [147] (chapter 3 of this thesis) where NCAM was found to be to be the most 
frequently occurring biomarker in biosignatures for the diagnosis of TB disease. Two of the 
host markers  included in the current biosignature (ferritin and A2M) are acute phase proteins 
that have previously been shown to have potential as biomarkers for the diagnosis of TB 
disease [111, 166]. Complement factor H is a soluble complement regulator important for 
controlling the alternative pathway [167] and has been included in a seven-marker 
biosignature for the diagnosis of TB disease in a serum- based study previously conducted in 
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our laboratory [82]. Taking the potential shown by these biomarkers in these previous studies 
as diagnostic candidates for TB disease into consideration, the findings from the present study 
indicate that the combination of host inflammatory protein biomarkers and TB-specific 
antibodies may enhance the diagnostic accuracy for TB disease. These observations require 
validation in future much larger studies. 
 
When investigated as potential candidates for monitoring of the response to TB treatment, 
antibodies against four M.tb specific antigens (Psts1, Apa, NarL and Rv3019c) showed 
potential, with IgA antibody responses against the proteins changing significantly during the 
course of TB treatment. To the best of our knowledge these antigens have not previously 
been investigated for as potential markers for monitoring of TB treatment response. 
Therefore further investigations are required in order to validate their usefulness as indicators 
of the response to TB treatment. As with other new biomarkers identified in the course of the 
work presented in this thesis, these TB-specific antibody responses should also be 
investigated for their potential as predictors of month 2 culture status and in differentiating 
between different treatment outcomes including cure and particularly unfavourable 
outcomes including relapse and patients at increased chances of treatment failure.  In 
addition for monitoring treatment response it might also be useful to look at antibody profiles 
together with cytokine profiles for evaluating an individual patient’s progress throughout 
treatment. 
 
Although the sample size investigated in the current study is considerably larger than sample 
sizes in most similarly published studies, our sample size of 152 may be seen as a limitation. 
Contrary to other published studies that were pure case-control studies, the current study 
made use of samples that were collected from individuals that presented at the primary 
health care centre with signs requiring investigation for TB, prior to the establishment of a 
clinical diagnosis. Our findings may therefore be very relevant but will require validation in 
larger studies, including studies conducted in other geographical regions. Incorporation of 
biosignatures comprising of anti-M.tb specific antibodies and host biomarkers into point-of-
care screening test platforms may be very useful in the control of TB disease. However, this 
can only be done after future larger validation studies. Such future studies should also include 
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more HIV infected individuals and patients presenting with symptoms that are often confused 
with TB including sarcoidosis and pneumonia as these patient types will be useful in 
estimating the specificity of the biosignatures. 
 
In conclusion we have identified biosignatures of anti-M.tb antibodies and combinations 
including antibodies and host inflammatory biomarkers which might be useful in the diagnosis 
of TB disease. The biosignatures identified in our study require further validation in larger 
























As highlighted in previous chapters, there is an urgent need for new tools for the rapid 
diagnosis of TB disease and monitoring of treatment response, especially in resource-
constrained settings. As diagnostic tests based on ex vivo inflammatory host biomarkers have 
the potential to be easily translated into diagnostic tools which are simple, easy to use and 
which may be easily converted into point-of-care (POC) diagnostic tools which would be 
suitable in resource-limited settings, the primary focus of these thesis was in investigating 
such biomarkers in plasma and saliva samples from individuals with presumed TB disease. 
Saliva is a readily available sample, which can be collected easily from all patients, including 
children, whereas the utility of plasma based biomarkers could be investigated in finger-prick 
blood, which will also enable easier utility of such a test in all patients.   
 
6.2 Summary of Main Findings 
 
In Chapter 3, the concentrations of 74 host biomarkers were investigated in plasma samples, 
as potential markers for the diagnosis of TB disease and monitoring of the response to TB 
treatment. Eighteen host markers showed potential as diagnostic candidates for TB disease 
as ascertained by area under the ROC curve (AUC); with the most promising being NCAM, 
CRP, SAP, IP-10, ferritin, TPA, I-309, and MIG, which diagnosed tuberculosis disease 
individually, AUC  ≥0.80. However, the main finding of the study was that a six-marker plasma 
protein biosignature comprising of NCAM, serum amyloid P, IL-1β, soluble CD40 ligand, IL-13 
and apolipoprotein A-1 diagnosed TB disease with a sensitivity of 100% (95% CI, 86.3-100%) 
and specificity of 89.3% (95% CI, 67.6-97.3%), irrespective of HIV status. In the absence of HIV 
infection, two different six-marker biosignatures comprising of NCAM, alpha-2-
macroglobulin, IL-22, ferritin, myoglobulin, IL-12(p40), and NCAM, alpha-2-macroglobulin, IL-
22, ferritin, TNF-β and MIP-4, diagnosed TB disease with both sensitivity and specificity of 
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100% (AUC = 1.0, 95% CI, 1.0-1.0). Furthermore, the concentrations of 11 of these host 
markers changed significantly during the course of treatment, thereby demonstrating their 
potential as tools to monitor TB treatment. In Chapter 4, we evaluated the concentrations of 
69 host markers as salivary biomarkers for the diagnosis of TB disease or monitoring of the 
response to treatment.  Of the 69 host markers that were investigated, the concentrations of 
23 were not detectable or just barely detectable, whereas eight were significantly different 
in saliva samples from TB patients and individuals with ORD. Although two markers (IL-16 and 
IL-23) showed promise individually as diagnostic candidates for TB disease as determined by 
AUC ≥0.70, the main finding of the study was a five-marker biosignature comprising of IL-1β, 
IL-23, ECM-1, HCC1 and fibrinogen which diagnosed TB disease with a sensitivity of 88.9% 
(95% CI,76.7-99.9%) and specificity of 89.7% (95% CI, 60.4-96.6%) after leave-one-out cross 
validation, regardless of HIV infection status, whereas eight-marker biosignatures performed 
with a sensitivity of 100% (95% CI, 83.2-100%) and specificity of 95% (95% CI, 68.1-99.9%) in 
the absence of HIV infection. Furthermore, the concentrations of 8 of the markers changed 
during treatment, indicating that salivary biomarkers may be useful in monitoring of TB 
treatment response. In Chapter 5, the diagnostic potential of antibodies against seven M.tb 
specific antigens namely; Apa, NarL, Rv3019c, PstS1, LAM and two other antigens whose 
identities have not yet been disclosed due to intellectual property concerns (“Kit 1” and “Kit 
2”), were investigated as tools for the diagnosis of TB disease and monitoring of the response 
to treatment. IgA antibody responses against four antigens (NarL, Rv3019c, “Kit 1” and “Kit 
2”) were significantly different between TB patients and individuals with ORD, with anti-NarL 
antibodies showing the most promise individually as diagnostic candidates, with an AUC of 
0.74, corresponding to a sensitivity of 92% (95% CI, 75-99%) and specificity of 52% (95% CI, 
34-60%). When antibodies against all seven proteins investigated were used in combination, 
the seven-antibody biosignature ascertained TB disease with an AUC of 0.8. When antibodies 
against the antigens were used in combination with clinical symptoms, anti-“Kit 1” IgA, anti-
“Kit 2” IgA, anti-Apa IgA, anti-NarL IgA in combination with night sweats and shortness of 
breath diagnosed TB disease with sensitivity and specificity of 85% (95%CI, 64.3-95% ) and 
71% (95% CI, 62-78.2% respectively after leave-one-out cross validation. When antibody 
responses were used in combination with host inflammatory biomarkers (“cytokines”), a six-
marker biosignature  comprising of a combination between anti-“Kit 1” IgA and five host 
markers (NCAM, vitronectin, complement factor H, ferritin and A2M diagnosed TB disease 
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with a sensitivity of 95% (95% CI, 73-100%) and specificity of 88.5% (95% CI, 68.7-97%) after 
leave-one-out cross validation. As observed with plasma and salivary host inflammatory 
biomarkers, antibodies against four of the M.tb specific antigens (Psts1, Apa, NarL and 
Rv3019c) also showed potential as candidate markers for TB treatment response.  
 
6.3 Significance of Findings from this Thesis: 
 
In this thesis, host inflammatory biomarkers detected in plasma and saliva as well as plasma 
antibodies against M.tb antigens were identified as diagnostic candidates for TB disease. 
Although individual host markers and antibodies showed promise, biomarkers identified in 
the different chapters of the thesis always performed better when used in combination. This 
therefore stresses the importance of any future TB diagnostic tests that could be developed 
from these biomarkers, to be based on combinations of analytes, rather than individual host 
markers and antibodies. As observed in chapter five, combinations between different classes 
of biomarkers (antibodies against M.tb antigens, used in combination with cytokines or 
symptoms) shows promise as a diagnostic approach.  The fact that the biosignatures 
identified in the present thesis were detectable in relatively non-invasive samples (plasma 
and saliva), is important, as such samples can be relatively easily collected from all patient 
types, even in remote settings. It will be ultimately most beneficial if these markers are 
incorporated into POC tests, which are suitable for use at the primary health care level, 
especially in high TB burdened and resource-constrained settings. Such tests should ideally 
be cost-effective lateral flow point-of-care tests that are capable of delivering results in 
minutes, on the same day. The earlier and faster diagnosis of TB disease implies that patients 
could start treatment earlier (ideally on the same day that they presented at the health care 
centre) and this will prevent further transmission of M.tb to their contacts. This thesis also 
demonstrated the potential of host markers and antibody responses against M.tb specific 
antigens as candidates to monitor treatment response. The use of these markers would 
therefore aid in knowing whether a patient is responding to treatment or whether the course 
of treatment should be altered. If such markers and antibodies are measured earlier, it will 
be informative and therefore more beneficial to TB control programs than the current 
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situation where a patient’s response to treatment is only assessed at month 2, and mostly 
using the poorly sensitive sputum smear microscopy test. These markers, if validated in future 
studies, will be also beneficial to TB drug manufacturers as it will be easier to assess if a new 
TB drug is working or not, thereby leading to shortening of the duration of clinical trials. 
However, the findings from this thesis are still preliminary as more validation studies still 
needs to be done. 
   
Overall, the diagnostic biosignatures identified in the present thesis performed with high 
negative predictive values. This means that these biosignatures, if incorporated into POC 
tests, would be useful as rule out tests for TB disease. Such a POC test would be able to 
identify patients that require confirmatory testing such as with the well-established tests  
(culture and GeneXpert), and may help in limiting the number of expensive tests usually 
performed in individuals suspected of having TB disease, as only about 30% of these 
individuals are finally diagnosed with TB. This approach will therefore lead to major cost 
savings. Such a POC test that is suitable for use at community level clinics is an urgent need 
as highlighted in the WHO target product profiles for new tests document that was published 
in 2014. The use of these ex vivo samples implies that such tests will be useful in diagnosing 
TB disease in patients having difficulty in providing good quality sputum, as well as diagnosing 
extrapulmonary TB, without the need for invasive techniques. However, further validation 
studies are required to refine the diagnostic biosignatures. 
 
As cytokines are produced by various immune cells, which influence the outcome of 
mycobacterial infection, the findings from this thesis have also helped in a better 
understanding of the pathogenicity of M.tb, specifically the host-pathogen interactions. Such 
interactions may provide insights into mechanisms of virulence, which could lead to 
innovative approaches for immunological intervention in TB disease. However, the 
investigation of the mechanisms of the disease, or the mechanisms influencing host 
inflammatory biomarker or antibody production were not the aim of the current thesis. 
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6.4 Future Investigations 
 
The main common limitation amongst all studies conducted as part of this thesis was the 
limited sample size. Although the sample sizes were not smaller than the sample sizes that 
are used in most published studies, it will be important that future studies are done in larger 
sample sizes. Furthermore, it is important that such studies include study participants 
recruited from different geographical regions. This will ensure that the refined and validated 
biosignatures and any tests developed based on the biosignatures are of global relevance. It 
will also be important that more HIV infected individuals are included into such future studies. 
As discussed in previous chapters, it will be important if HIV infected participants included in 
such future studies are staged with CD4 cell counts and viral loads, so as to investigate the 
influence of severe HIV infection on the accuracy of the host biosignatures. Future 
investigations in patients with other comorbidities such as diabetes would also be of 
significance. Furthermore, the TB patients investigated in this thesis were all adults, with 
confirmed pulmonary TB. Therefore it cannot be ascertained from the findings of the current 
thesis whether these host biosignatures would be useful in children with paediatric TB, and 
those with extrapulmonary disease. There is therefore a need for investigation of the 
diagnostic potential of the identified biosignatures in children and in patients with 
extrapulmonary TB disease. Furthermore, as previously discussed in the thesis, it will also be 
important if patients presenting with confirmed diseases that are similar to TB, including non-
TB pneumonias are included in future studies.  This is because the ORD groups investigated 
in this thesis lacked firmly established alternate diagnoses, even though they all presented at 
the clinic with symptoms requiring investigation for TB. Such a group of study participants 
would be important in order to ascertain the specificity of the host biosignatures for the 
diagnosis of TB.  Further larger studies would also be required to investigate the potential of 
host markers as tools to monitor the response to TB treatment, and should also include 
samples that are recruited at earlier time points. Additional investigations should also look at 
the abilities of the host markers to predict month 2 culture status as well as final treatment 
outcome (clinical cure, relapse or treatment failure). It will be important that markers 
identified in plasma are also investigated in finger-prick blood, as this approach is planned to 
be investigated in a study that is currently ongoing in the Stellenbosch University immunology 
research laboratory as well as laboratories in other African and European countries 
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(www.screen-tb.eu), the markers identified in the current thesis could form part of the panels 
planned to be investigated in such larger studies, with the ultimate aim being the 
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